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Abstract 
Research Involving Children: Regulations, Review Boards and Reform. Rupali Gandhi 
(Sponsored by Dr. Robert J. Levine). Department of Internal Medicine, Yale University, School of 
Medicine, New Haven, CT. 
Children have been the victims of unethical clinical investigations since the earliest 
clinical research trials. Although children are vulnerable and require additional protections 
when participating in research, they should not be disallowed from research altogether because 
this is more detrimental to their well being than permitting their participation. The ethical 
principles of respect for persons, beneficence and justice serve as the foundation for the federal 
regulations, adopted in 1981, which serve to protect human subjects in research. Although the 
regulations were a vast improvement over prior codes, they continue to use an array of vague 
language that leaves substantial room for debate in their interpretation. Several hypothetical 
cases and two recent controversial cases exemplify how reasonable people continue to disagree 
over how the regulations should be interpreted and applied. One problem with the current 
review system is its almost total reliance on the efficiency and knowledge of local institutional 
review boards. The creation of a hierarchical review board system that maintains the local 
institutional review boards (IRBs) but creates many regional boards and one national board 
analogous to the federal court structure will have a positive impact on the current regulatory 
system. The establishment of a more centralized system that still maintains a degree of flexibility 
will encourage greater consistency between interpreters of the regulations, provide an appeals 
process for individual investigators, and create one national board with the requisite case 
experience and knowledge of how the regional and local review boards operate to enable it to 
promulgate memoranda that clarify the interpretation of the federal regulations as needed. 
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Introduction 
Historical Perspectives: Past to Present 
Children have been the victims of unethical clinical investigations since the earliest 
clinical research trials.1 In 1789, Edward Jenner, an English researcher trying to discover a 
vaccination for smallpox, initially injected his own one-year-old son with cowpox to determine 
whether it would offer protection against smallpox. Next, he gave an eight-year-old child a 
challenge of smallpox material to see if a prior vaccination would be effective. Later, in 1802, a 
physician for an almshouse gave the vaccine to 48 children who were under his care and later 
challenged the vaccine by inoculating the children with smallpox material.2 3 Although these 
initial vaccination trials posed obvious danger to the children who were inoculated, the trials 
were justified by arguing that the possible benefits to children as a group outweighed the risks 
inflicted on the few children who were the initial subjects. 
Although research on children continued, there were at least some physicians who 
objected to the use of children in medical experiments in which subjects were purposely injured 
in order to obtain scientific evidence for a disease course. In 1941, the editor of the Journal of 
Experimental Medicine, Francis Payton Rous, wrote in his rejection of a manuscript that "the 
inoculation of a twelve month old infant with herpes... was an abuse of power, an infringement 
of the rights of an individual, and not excusable because the illness which followed had 
implications for science."1 His opinion, however, had little impact on the academic community 
and the research results were published in the Journal of Pediatrics.4 
From the 1950s through the 1970s a set of experiments were conducted at the 
Willowbrook State School, a New York State institution for mentally disabled children. The 
1 See Leanord H. Glantz , Research With Children, 24 AM. J.L. & MED. 213, 215 (1998). See also Susan 
E. Lederer & Michael Grodin, Historical Ovennew: Pediatric Experimentation, in CHILDREN AS RESEARCH 
Subjects: Science, Ethics and Law 3 (Michael A. Grodin & Leanard H. Glantz eds., 1994). 
2 See Lederer & Grodin, supra note 1, at 5. 
3 See id. at 14. 
4 See id. 
- 
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research was intended to help elucidate the natural course of hepatitis." Researchers 
systematically infected mentally disabled children with a hepatitis virus. Early subjects were 
given extracts of stool from infected persons, and later subjects were injected with purified virus 
preparations.5 6 7 8 9 The researchers justified their actions by claiming that 85% of the children in the 
institution would contract the disease in the first year of admission anyway, and systematic 
infection would allow the investigators to study the natural course of the disease. The institution 
was closed to new children because of its overcrowded conditions, but the hepatitis program, 
with its own space in the building, was able to admit new members. Therefore, in order to have a 
child accepted to Willowbrook, parents often had to accept their child's participation in the 
hepatitis program.' When the Willowbrook experiments were brought to public attention in the 
1970s there was a huge outcry.* It was unimaginable that innocent children had intentionally 
been given a serious illness and their parents, desperate to find care for their disabled children, 
had been coerced into permitting their participation. Furthermore, the researchers' justification 
that the children would have likely contracted hepatitis anyway only emphasized the terrible 
unsanitary conditions in which these mentally disabled children were housed. Finally, the legal 
authority of parents to volunteer their children for this research was questioned.^ 
As these examples reflect, children have not been adequately protected from unethical 
clinical research. It is not enough to believe that researchers will conduct their work with 
adequate protection for children on their own accord. Eliot Friedson writes that the professional 
5 See id. at 17. See also Robert J. Levine, Ethics and Regulation of Clinical Research, 70 (Yale 
Univ. Press 2d ed. 1988) (1986). 
6 See Levine supra note 5, at 70. 
7 See id. 
8 Some results from the Willowbrook studies had been published in the New England Journal of Medicine 
in 1958 with few if any objections, but after the public took notice in the 1970s, “a furor attends the 
appearance of any Willowbrook report, even though the report may present no more than the results of 
continued surveillance of children infected at an earlier date.” F.J. Ingelfmger, Ethics of Experiments on 
Children, 288 New ENGLAND J. MED. No. 15, 791. 
9 See, e.g., Glantz, supra note 1 at 217. But see id. at 792. Ingelfmger writes that even after the public 
outcry some researchers believed that the risks imposed on the children were permissible given the risks of 
being a patient in the unsanitary conditions of Willowbrook. He states that perhaps “some broadly based 
system can be set up to determine under what conditions children or mentally incompetent persons can be 
used for experimentation not primarily designed for their benefit. This is the only reasonable way; it is also 
the only honest way.” 
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privilege of self-regulation has been justified on several grounds including that the profession 
"may be trusted to undertake the proper regulatory action on those rare occasions when an 
individual does not perform his work competently or ethically."10 He is skeptical, however, that 
self-regulation works in medicine because the ability to observe performance is a prerequisite for 
regulation, and he doubts that the structure of the medical profession has an appropriate level of 
observability.11 Furthermore, he asserts that medical norms seem to discourage self-regulation.12 
Talcott Parsons, by contrast, argues that professions are limited from perfect efficiency due to 
social constraints.1' The profession's ability to function appropriately depends on an institutional 
structure "the maintenance of which...involves a complex balance of diverse social forces."14 
Certainly, institutional review boards (IRBs) are a form of self-regulation by the medical 
community to ensure that investigators engaged in research protect the rights and welfare of 
human subjects. Although many would assert that they do an admirable job, several IRBs have 
been accused of not protecting human subjects adequately.1' Perhaps, however, it is not that self¬ 
regulation is impossible or undesirable, but rather the institutional structure of the regulatory 
system that needs to be recalibrated. 
Unfortunately, examples of unethical research involving children are not only in the 
distant past. The truth remains that even with protections that were adopted into law in the early 
1980s there remain incidents where children have been the subjects of research deemed unethical. 
The existence of the current federal regulations does not guarantee that there will be compliance 
with the spirit underlying the words of the regulations or complete agreement over what 
constitutes ethically acceptable research. The current system relies heavily on IRBs to function 
appropriately and interpret the federal regulations with careful deliberation. Case examples, 
10 See Eliot Friedson, Profession of Medicine: A Study of the Sociology of Applied Knowledge, 
137 (Univ. of Chicago Press 1988). 
11 See id. at 157. 
12 See id. at 184. 
13 See Talcott Parsons, Essays in Sociological Theory, 35 (Free Press rev. ed. 1954) (1949). 
14 Id. at 48. 
15 One might argue, however, that inherent uncertainties in medical practice, knowledge and research 
would lead to less-than-perfect outcomes even //IRBs functioned flawlessly. See Jay Katz, The Silent 
World of Doctor and Patient 171 (Free Press 1984). See also Levine supra note5, at 127-128. 
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however, demonstrate that reasonable people can and do disagree over how the regulations 
should be interpreted and what types of research protocols are ethically permissible. Most 
recently, a study of housing lead abatement conducted by affiliates of Johns Hopkins University 
engendered differing opinions over what should be ethically acceptable.1'' Additionally, a 
National Institute of Child Health and Human Development study using obese children and 
children of obese parents was terminated for violating the federal regulations.1 This paper will 
explain the special problems of involving children in research, provide a thorough understanding 
of some of the past and current protections for human clinical research participants including the 
current federal regulations, emphasize the more controversial areas, and make recommendations 
on how the regulatory structure could be improved. 
Part I will describe why children are unique in the research world. It will argue that 
while children are vulnerable and require additional protections when participating in research, 
they should not be disallowed from research altogether because this is more detrimental to their 
well being than permitting their participation. Rather, children should be permitted to 
participate in research but with additional safeguards in place that protect their vulnerable 
situation. 
Part II describes the historical context of human research protections including the 
Nuremberg Code and the Declaration of Helsinki. It explores the ethical principles that have 
been used to protect humans involved in clinical research and explains how these principles of 
respect for persons, beneficence and justice are applied to persons with diminished capacity, such 
as children. The unique characteristics of children make the application of these principles less 
straightforward than when applied to research involving adults and their expression in 
procedural and substantive norms is necessarily altered when applied to children. 
The current federal regulations that govern human clinical trials involving children will 
be scrutinized in Part III. The regulations were passed in the early 1980s, but were preceded by 
16 See infra note 73 and accompanying text. 
17 See infra note 91 and accompanying text. 
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recommendations made by a national commission that was created several years earlier in the 
aftermath of the Tuskegee syphilis experiments. Although the regulations were a vast 
improvement over prior codes, they continue to use an array of vague language that leaves 
substantial room for debate in their interpretation. Several hypothetical cases and recent 
controversial cases will be used to exemplify how reasonable people continue to disagree over 
how the regulations should be interpreted and applied. 
Finally, Part IV offers recommendations for change within the regulatory system. The 
creation of a hierarchical review board system that maintains the local institutional review boards 
but creates many regional boards and one national board analogous to the federal court structure 
will have a positive impact on the current regulatory system. The establishment of a more 
centralized system that still maintains a degree of flexibility will divide the duties between the 
review boards according to their strengths, encourage greater consistency between interpreters of 
the regulations, provide an appeals process for individual investigators, and create one national 
board with the requisite case experience and knowledge of how the regional and local review 
boards operate to enable it to promulgate memoranda that clarify the interpretation of the federal 
regulations as needed. 
Part I: Children in Research 
Children are distinct from other human research subjects because they do not usually 
have the maturity and knowledge base to make an informed decision. They are "incapacitated" 
in the sense that one would not expect a five-year-old child to be able to comprehend, process, 
engage in abstract reasoning or synthesize information in the same way as a twenty-five-year-old 
person. Children cannot be expected to make fully informed decisions regarding their own 
participation in clinical trials that may or may not be of direct benefit to them. Surely, some 
children will express opinions, but children can often be guided into making a decision based on 
the viewpoint of a trusted adult or parent. In order to ensure that a child truly understands what 
' 
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is being asked of him and is not being coerced or improperly informed, special protections or 
cautions must be used when children are research subjects. 
Given the multiple examples where children have been mistreated in clinical research 
trials, one might argue that children should not be permitted to participate in human 
investigations at all. This approach, seemingly radical in the modern world, was indirectly 
supported by the Nuremberg Code.1* Despite the desire to protect children from the possible 
harms that can result from their participation in research, there are far more detrimental effects 
that would result if children were prohibited from participation in human clinical investigations 
altogether. 
If research involving children (or any group having biological differences from the 
"average" such as pregnant women) were disallowed, the medical progress for that population 
would be halted as well. Diseases such as cystic fibrosis, phenylketonuria, Hirschprung's disease 
and many congenital anomalies first manifest in childhood and if they are not treated early, the 
child may not ever reach adulthood. In order to make advances in the treatment of these 
diseases, a research study needs to enroll children who have the diseases in question. Without 
such research, the children become "therapeutic orphans."1" They are left behind while medicine 
advances for everyone else. 
Furthermore, beyond research on childhood diseases, there is another category of 
essential research - medication use in children - that lags far behind. Presently, most 
medications used for children are used "off-label," meaning that they were never formally tested 
on children; rather the adult doses are modified and then given to the child. Since 1962, the FDA 
has required nearly all new drugs to be labeled with an "orphaning" clause such as "not 
recommended for use in infants or children, since few studies have been carried out in this 
18 Although the Nuremberg Code was silent with regard to children, it required legally capacity to give 
consent for participation, and therefore, indirectly prevented children (who cannot legally consent) from 
participation. See Appendix 2 for text of Nuremberg Code. 
19 See Harry Shirkey, Editorial Comment: Therapeutic Orphans, 72 J. OF PEDIATRICS No. 1, 119 (1968). 
See also Levine, supra note 5, at 239-241. 
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group..."2'1 Nevertheless, the overwhelming majority of physicians ignore the orphaning clause 
on the labels and use the medications for children anyway, albeit, usually at an adjusted dose. 
The result of off-label usage is that it produces a greater risk to the child than if the child had been 
part of a well-designed research protocol that tested different medication doses to determine the 
appropriate level to be used. A child in a research study designed to test the best dose of a 
medication would likely have more information about the medication, frequent surveillance of 
side effects and a greater likelihood of having access to medical care should an adverse reaction 
develop. Children given a medication off-label, however, do not have the same surveillance of 
side effects and risk a greater possibility of harm if an adverse reaction occurs in an uncontrolled, 
unmonitored setting. Robert Levine argues that the therapeutic orphan problem is a serious 
injustice. He observes that "[i]f we consider the availability of drugs proved safe and effective 
through the devices of modern clinical pharmacology and clinical trials a benefit, then it is unjust 
to deprive classes of persons, e.g., children...of this benefit."21 
The problem with the lack of clinical pharmacology studies in children is even more 
concerning than the dearth of studies involving other vulnerable groups (such as prisoners or 
mentally disabled individuals) because children often have smaller body sizes, different 
physiology and different metabolisms (for example, the newborn liver does not metabolize 
certain medications as efficiently as the adult liver), therefore improper medication doses for 
children could lead to grave consequences more often than with adults. Logically then, it 
appears that medications used in children should have more stringent testing than medications 
used for adults. Yet the opposite is true: medications used for children have the least amount of 
empirical evidence supporting their use. 
20 See Shirkey, supra note 19, at 119. 
21 See Levine, supra note 5, at 239. Levine states: “Parenthetically, it should be noted that most drugs 
proved safe and effective in adults do not produce unexpected adverse reactions in children; however, when 
they do, the numbers of harmed children tend to be much higher than they would be if the drugs had been 
studied systematically before they were introduced into the practice of medicine.” Id. at 240-241. 
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The Best Pharmaceuticals for Children Act of 2002“ gives financial incentives to 
pharmaceutical companies that voluntarily decide to test their medications in children, but this 
law clearly has not done enough considering that as of July 2003, three-fourths of all prescription 
medications on the market had inadequate information regarding their safety in pediatric 
populations.2' In 1998, the Food and Drug Administration (FDA) had attempted to alleviate the 
problem by adopting a regulation known as the Pediatric Rule. The Rule required 
pharmaceutical companies to test specific medicines in children before the drugs were marketed. 
In October 2002, however, a judge ruled that the FDA did not have the authority to adopt the 
Pediatric Rule and so it was struck down. Congress reacted, albeit slowly, and adopted the 
Pediatric Research Equity Act of 2003 which was signed into law just recently in December 2003. 
The law gives the FDA jurisdiction to require that drugs used in pediatric patients be 
appropriately tested with pediatric populations prior to FDA approval. Recognizing the 
importance of solving the therapeutic orphan problem, FDA Commissioner Mark McClellan 
stated: 
Prescription drugs can do more than ever to cure diseases, 
including illnesses in children. But it is not good medicine to 
assume that children can be treated like little adults. Parents and 
health professionals deserve confidence that medicines used to 
treat children are safe and effective. FDA will use this important 
new law to require pediatric studies, when necessary, to give 
parents and doctors the confidence they deserve.24 
Undoubtedly, the Pediatric Research Equity Act is a step in the right direction towards 
alleviating the therapeutic orphan problem and decreasing off-label medication use and its 
associated risks. The law will lead to increased numbers of research trials involving children, 
and although these studies should be conducted to benefit children, additional safeguards must 
"2 Best Pharmaceuticals for Children Act, Pub. L. No. 107-109, (codifed as amended in scattered sections 
of 21 U.S.C.) (text also available at: <http://www.fda.gOv/opacom/laws/pharmkids/pharmkids.html#secl>). 
23 Participation and Protection of Children in Clinical Research, Before the Inst, of Med. Comm, on 
Clinical Research Involving Children (July 9, 2003) (statement of David J. Schonfeld, member of the Am. 
Acad, of Pediatrics Comm, on Pediatric Research) (text available at 
<http://www.aap.org/advocacy/washing/David_Schonfeld_testimony.htm>). 
■ 
' 
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be in place to prevent their manipulation and exposure to unreasonable levels of possible harm. 
The balance between encouraging research designed to help children as a group and preventing 
unreasonably high levels of risk to any particular child in a study is difficult to strike. Ethical 
principles can serve an important role by guiding decision-makers during difficult assessments. 
Part II: Foundations of Research Ethics 
From 1945-1947, the first international war-crimes trials were held in Nuremberg, 
Germany in order to bring justice to the Nazis who committed terrible offenses during World 
War II. Many of the crimes included horrific murders and tortures conducted in the name of 
medical research. The three Nuremberg judges were infuriated by the atrocities committed using 
science as a justification and decided to codify fundamental ethical guidelines for permissible 
human research "in order to satisfy moral, ethical and legal concepts."1' The Nuremberg Military 
Tribunal's decision in United States v. Karl Brandt et al. included a ten-point statement that 
described permissible medical experiments on human subjects. These ten principles became 
known as the Nuremberg Code, and the Code is generally regarded as the first international 
document to set out ethical regulations in human experimentation based on informed consent.2h 
(See Table 1.) 
24 Press release on the signing of the Pediatric Research Equity Act of 2003 (Dec. 3, 2003) (statement of 
Mark B. McClellan, Commissioner of the Food and Drug Administration) (text available at 
<http://www.fda.gov/bbs/topics/NEWS/2003/NEW00989.html>). 
25 Nuremberg Code. Reprinted in Levine, supra note 5, 425-426. See Appendix 2 for full text of 
Nuremberg Code. 
26 The Nuremberg Code, however, was not the first document to outline the obligations of researchers 
conducting human clinical investigations. In fact, federal law in German already included such obligations 
and prohibitions against unethical research but these laws were ignored during the Third Reich. See 
Levine, supra note 5, at 69. 
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Table 1: Influential Documents on Research Ethics 
Year Publication Author Description 
1947 Nuremberg Code Nuremberg judges First major international code of 
research conduct created after 
Nuremberg trials of Nazi 
physician/ researchers 
1964 Declaration of 
Helsinki 
World Medical Association Comprehensive ethical 
guidelines for physicians 
involved with research, last 
updated in 2000 
1979 Belmont Report The National Commission for the 
Protection of Human Subjects of 
Biomedical and Behavioral 
Research from the Department of 
Health, Education, and Welfare 
Report that identified key 
principles for guiding human 
research protection, including 
respect for persons, beneficence, 
justice' 
The first principle of the Nuremberg Code states: "The voluntary consent of the human 
subject is absolutely essential."28 The term "voluntary" is further elaborated: 
This means that the person involved should have legal capacity 
to give consent; should be so situated as to be able to exercise 
free power of choice, without the intervention of any element of 
force, fraud, deceit, duress, overreaching, or other ulterior form 
of constraint or coercion; and should have sufficient knowledge 
and comprehension of the elements of the subject matter 
involved as to enable him to make an understanding and 
enlightened decision.24 
This principle, although well intentioned, is extremely overbroad because, taken literally, it 
would prohibit all research involving those who are unable to consent including children and the 
mentally disabled who are unable to give informed legal consent. The Code makes no exceptions 
for proxy consent or consent for minors to be given by parents. Investigators, therefore, have 
largely ignored this principle of Nuremberg Code and continued to conduct research using these 
populations. Even though the authors may be admired for attempting to codify basic ethical 
principles, the overall impact of the Nuremberg Code on actual research practices has been 
minimal. One scholar also points out that "the very circumstances that gave the code its high 
27 See Julie Rothstein Rosenbaum, Educating Researchers: Ethics and the Protection of Human Research 
Participants, 31 CR1T. Care Med. No. 3, Suppl. At SI62 (2003). 
28 See Nuremberg Code, supra note 25. 
29 See id. 
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moral standing - the horrors that surrounded its origins - partly account for its relative lack of 
influence in the postwar years: ordinary researchers found it hard to believe that the code need 
be applied to their own work/'10 
In response to the overly restrictive Nuremberg code, the World Medical Association 
adopted the Declaration of Helsinki in 1964.31 The Declaration emphasizes the importance of 
freely given informed consent by research subjects, but it parts with the Nuremberg Code in an 
important way: 
In case of legal incompetence, informed consent should be 
obtained from the legal guardian in accordance with national 
legislation. Where physical or mental incapacity makes it 
impossible to obtain informed consent, or when the subject is a 
minor, permission from the responsible relative replaces that of 
the subject in accordance with national legislation.1' 
The Declaration of Helsinki implicitly acknowledges that research on groups who are unable to 
give consent is necessary to advance medical care for these groups and provides a method for 
obtaining proxy consent. It serves as a more practical guide to researchers and tries to alleviate 
the problem of the therapeutic orphan. Nevertheless, even after the Declaration of Helsinki was 
written, pediatric research was rare in the United States because the legal status of proxy consent 
remained uncertain. 
Another important feature of the Declaration of Helsinki was its division of research into 
therapeutic and non-therapeutic categories. The 1975 revised Declaration divides research into 
"Medical Research Combined with Professional Care (Clinical Research)" and "Nontherapeutic 
Biomedical Research Involving Human Subjects (Nonclinical Biomedical Research)." For the first 
category of research (therapeutic research), the physicians can perform research "only to the 
extent that medical research is justified by its potential diagnostic or therapeutic value for the 
30 Kendall A. Desaulniers, Legislation to Protect the Decisionally Incapacitated Individual’s Participation 
in Medical Research: Safety Net or Trap Door? 13 REGENT U.L.REV. 179, 182 (2000-2001). 
31 See Human Experimentation: Code of Ethics of the World Medical Association, 2 BRIT. Med. J. 177 
(1964). See also Declaration of Helsinki (1975), reprinted in Levine, supra note 5, 427-429. The 
Declaration of Helsinki has been revised several times, most recently in 2000. See Appendix 3 for full text. 
32 See Declaration of Helsinki, supra note 31, at 428, Part I. Basic Principles, No. 11. 
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patient."33 In the non-therapeutic category, however, the subjects must be "healthy persons or 
patients for whom the experimental design is not related to the patient's illness."34 The distinction 
between therapeutic and non-therapeutic research has the unfortunate consequence of 
prohibiting all placebo-controlled studies because the placebo arm is not of therapeutic value to 
the patient, and using healthy control subjects for the placebo arm of a trial would yield no useful 
information.34 Levine explains that the therapeutic/non-therapeutic distinction essentially 
prohibits all research in pathogenesis, pathophysiology and epidemiology because these types of 
studies usually will not have therapeutic value for the research subjects.3" Levine further clarifies 
that every clinical trial has components that are not therapeutic, but to then classify the entire 
protocol as therapeutic just because it has one therapeutic component results in the "fallacy of the 
package deal."37 Non-therapeutic components of a protocol are commonly justified because the 
protocol includes one or more therapeutic components. Levine provides some examples: 
Such erroneous justifications in the recent past have been 
frequent. In trials of thrombolytic therapy, repeated coronary 
angiograms have been performed on patients who had clinical 
indications for only one. Liver biopsies have been performed for 
no reason other than to disguise treatment assignments in a 
double-blind placebo-controlled trial. Repeated endoscopies 
have been performed in a population of patients with peptic 
ulcers who had clinical indications for no more than one. 
Placebos have been administered by way of a catheter inserted 
in the coronary artery. I do not want to be misunderstood as 
saying that any of these procedures were unethical. I am simply 
arguing that they should not be justified according to standards 
developed for "therapeutic research."38 
The Declaration of Helsinki was most recently revised in October 2000. Despite some changes 
adopted in this sixth edition, the Declaration remains restrictive of placebo trials. In addition. 
33 Id. at 429, Part II. Medical Research Combined with Professional Care (Clinical Research), No.6. 
34 Id. at 429, Part III. Nontherapeutic Biomedical Research Involving Human Subjects (Nonclinical 
Biomedical Research), No. 2. 
35 Levine, supra note 5, at 9. 
36 See id. See also Robert J. Levine, International Codes of Research Ethics: Current Controversies and the 
Future, 35 Ind. L. Rev. 557, 560 (2002). See also Declaration of Helsinki, supra note 31, §§ II.6 and III 2. 
37 Levine, supra note 36, at 560. 
38 Id. 
' 
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although it removed the words "therapeutic" and "non-therapeutic," it still uses the distinction to 
determine what research is permissible. " 
Though they served as important advances in the conceptual framework for ethical 
research, the Nuremberg Code (1947) and the Declaration of Helsinki (1964) were never legally 
binding documents and were not able to halt the research abuses that were already underway 
and continued until the 1970s such as the Tuskegee Syphilis Study and the Willowbrook School 
study on children.41' The ethical codes of Nuremberg and Helsinki were not powerful enough to 
stop the egregious devaluing of human life that these research studies exemplified. In the 
aftermath of these studies, a modem code that was legally binding was needed to govern 
research ethics and renew the public's trust in medical research. 
The National Commission and Ethical Principles 
The Department of Health, Education and Welfare (DHEW) published the first proposed 
regulations on protection of human subjects in 1973. When the atrocities of the Tuskegee 
experiments came to light. Congress held national hearings on human clinical research, and 
eventually adopted the National Research Act of 1974 (Public Law 93-348), which created the 
National Commission for the Protection of Human Subjects of Biomedical and Behavioral 
Research [hereinafter "Commission"]. The Commission was to develop guidelines for ethical 
research involving human subjects and make recommendations to the DHEW Secretary for the 
application of these guidelines.41 Section 202(a)(1)(A) of the National Research Act specified that 
the Commission should: 
39 See id. at 559. 
40 The Tuskegee Syphilis experiment began in 1932 and was designed to measure the results of untreated 
syphilis in black males who were uneducated sharecroppers. The protocol in this trial included a placebo 
arm where subjects were given aspirin instead of proven treatments for syphilis. Furthermore, the 
researchers did not stop the trial and give subjects penicillin when it was discovered in the 1940s. The 
study did not receive press attention until 1972. See supra notes 5-9 and accompanying text for discussion 
of the Willowbrook studies. 
41 See The National Commission for the Protection of Human Subjects of Biomedical and Behavioral 
Research: Research Involving Children: Report and Recommendations. DHEW Publication No. (OS) 77- 
0004 at xvii, [hereinafter Report on Research Involving Children] Washington, D.C. (1977). 
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(i) conduct a comprehensive investigation and study to 
identify the basic ethical principles which should 
underlie the conduct of biomedical and behavioral 
research involving human subjects, 
(ii) develop guidelines which should be followed in such 
research to assure that it is conducted in accordance 
with such principles, and 
(iii) make recommendations to the Secretary (I) for such 
administrative actions as may be appropriate to apply 
such guidelines to biomedical and behavioral research 
conducted or supported under programs administered 
by the Secretary.. .42 
The Commission published reports on human subject research from 1975-1978 and presented the 
reports as recommendations to the DHEW Secretary as it was instructed.4' The Commission 
addressed topics such as IRBs, research on the fetus and embryo, and research involving 
children. The Commission was disbanded in 1978 but during its brief years of existence it made 
valuable contributions to the discussions of research ethics and suggested possible regulatory 
guidelines. 
The Commission's Belmont Report: Ethical Principles and Guidelines for the Protection 
of Human Subjects Research (1979) described three ethical principles that should guide research 
involving human subjects: respect for persons, beneficence, and justice. The first of these, respect 
for persons, requires that individuals be treated as "autonomous agents" and also that "persons 
with diminished autonomy and thus in need of protection are entitled to such protection."44 To 
treat a person as an "autonomous agent" requires that the individual be left alone, even if doing 
so may result in harm to that person, unless he/she consents to receive help or participate.4’ 
Furthermore, a person's actions should not be hindered unless they are clearly detrimental to 
others.41' Certainly, not every person has the ability to act as an "autonomous agent" and it is this 
42 Levine, supra note 5, at xii. 
43 Importantly, the Commission explicitly repudiated the use of therapeutic and non-therapeutic categories 
of research after using the distinction in its first report on research involving fetuses. 
44 See The National Commission for the Protection of Human Subjects of Biomedical and Behavioral 
Research: The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of 
Research. DHEW Publication No. (OS) 78-0012 Washington, D.C. (1978) [hereinafter Belmont Report] 
(text also available at <http://ohrp.osophs.dhhs.gov/humansubjects/guidance/belmont.htm>). 
44 Levine, supra note 5, at 15. 
46 See id. at 16. 
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subset of people that require additional protections because without them, they are far more 
likely to have their person disrespected/' Because research involving children involves persons 
with diminished autonomy, children deserve extra protections when they participate in such 
research. 
The second ethical principle, beneficence, is understood to mean that the researcher 
should maximize possible benefits and minimize possible harms.48 It is important to recognize 
that this principle is more than simple non-maleficence; it also imposes a positive duty on the 
researcher to maximize benefits and minimize harms. The Belmont Report recognizes that this is 
not always a simple task and that researchers will need "to decide when it is justifiable to seek 
certain benefits despite the risks involved, and when the benefits should be foregone because of 
the risks."41' The Belmont Report allows the benefit to society to be considered in the equation 
when balancing risks and potential benefits involved/11 
Justice, the third basic principle, requires that subjects are chosen and treated fairly. 
Justice is essential to "insure that certain individuals or classes of individuals - such as prisoners, 
elderly people, or financially impoverished people - are not systematically selected or excluded, 
unless there are scientifically or ethically valid reasons for doing so."51 This concept of justice is 
meant to provide an equal distribution of the benefits and burdens that accompany research. The 
Commission did not interpret justice in a utilitarian way to mean the greatest good for the 
greatest number of people because this view ignores the idea that fairness requires extra 
protections for vulnerable groups.52 The Commission concluded that: 
persons having limited capacity to consent are vulnerable or 
disadvantaged in ways that are morally relevant to their 
involvement as subjects of research. Therefore, the principle of 
47 Id. Levine argues: “The capacity of self-determination matures during a person’s life; some lose this 
capacity partially or completely owing to illness or mental disability or in situations that severely restrict 
liberty, such as prisons. Respect for the immature or the incapacitated may require one to offer protection 
to them as they mature or while incapacitated.” 
48 See Belmont Report, supra note 44. 
49 See id. 
50 See Declaration of Helsinki, supra note 31. See also Desaulniers, supra note 30, at 203. 
51 See Belmont Report, supra note 44. 
52 Levine, supra note 5, at 18. 
' 
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justice is interpreted as requiring that we facilitate activities that 
are designed to yield direct benefit to the subjects..."' 
These three principles of respect for persons, beneficence and justice have provided the 
ethical framework for human clinical research, and as noted by the Commission, these principles 
require additional safety measures to protect vulnerable populations involved in research. The 
Commission's reports and suggestions, which were later adapted and adopted into the Code of 
Federal Regulations, rely heavily on the ethical principles. 
In 1980, DHEW was restructured; education became a separate department, and what 
remained of DHEW became the Department of Health and Human Services (DHHS). Shortly 
thereafter, in 1981, DHHS published federal regulations on the protection of human subjects that 
were mostly an adoption of the Commission's suggestions. These initial federal regulations did 
not include special regulations for children, but regulations for children were finally approved 
two years later in 1983.44 
Although the Code of Federal Regulations attempts to provide boundaries between 
acceptable and unacceptable research, there will always be research protocols that do not fall 
neatly into these categories. It is precisely when the regulations do not provide clear answers 
regarding the acceptability of a particular research protocol that the three ethical principles 
become even more important; they should serve as guidance when the regulations are 
ambiguous. 
Part III: Federal Regulations 
Additional Protections for Children Involved as Subjects in Research: 
The Commission's report, Research Involving Children (1977), made recommendations 
that allow children to be used in research, yet still protect them adequately from harm. The 
recommendations served as the basis for the Code of Federal Regulations (CFR) Subpart D: 
53 See Belmont Report, supra note 44. See also LEVINE, supra note 5, at 236. 
54 LEVINE, supra note 5, at xii. See also Report on Research Involving Children, supra note 41. 
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Additional Protections for Children Involved as Subjects in Research (1983). Unlike the 
Nuremberg Code and the Declaration of Helsinki, the regulations are legally binding, yet they 
are not without their own flaws. The main purpose of the Subpart D is to provide children, as 
members of a population considered vulnerable, with additional safeguards. The section divides 
research involving children into four categories, each of which has different requirements for 
approval. (See Table 2.) Section 46.403 further requires that IRBs only approve research that 
satisfies the requirements set forth in the remainder of Subpart D. 
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Table 2: Federal Regulations for Research Involving Children 
Federal 
Regulation 
Section 
Risk Posed by 
the 
Intervention or 
Procedure 
Additional Requirements for Protocol 
Approval 
(*A11 require IRB approval, child's assent” and 
permission by parent or guardian^) 
45 CFR §46.404 No greater than 
minimal risk 
No additional requirements 
45 CFR §46.405 Greater than 
minimal risk with 
prospect of direct 
benefit to subject 
1. Risk is justified by the anticipated benefit to each 
subject 
2. Anticipated benefit to each subject is at least as 
favorable as that presented by available 
alternative approaches 
45 CFR §46.406 Greater than 
minimal risk with 
no prospect of 
direct benefit to 
subject 
1. Risk represents a minor increase over minimal 
risk 
2. Intervention or procedure presents experiences to 
the child that are reasonably commensurate with 
those in the child's actual or expected medical, 
dental, psychological, social or educational 
situations 
3. The study is likely to yield generalizable 
knowledge about the child's disorder or condition 
that is of vital importance for the understanding 
or amelioration of the disorder or condition 
45 CFR §46.407 Research not 
otherwise 
approvable 
1. IRB finds that the research presents a reasonable 
opportunity to further the understanding, 
prevention, or alleviation of a serious problem 
affecting the health or welfare of children 
2. Approval of the Secretary of DHHS after 
consultation with a panel of experts in pertinent 
fields, and following opportunity for public 
review and comment’ 
The drafters of the regulation, following the lead of the Commission, refrained from 
using the distinction between therapeutic/non-therapeutic research and thereby avoided the 
"fallacy of the package deal" that is created with the Declaration of Helsinki language and others 
55 45 CFR §46.408. Requirements for permission by parents or guardians and for assent by children: In 
addition to the determinations required under other applicable sections of this subpart, the IRB shall 
determine that adequate provisions are made for soliciting the assent of the children, when in the judgment 
of the IRB the children are capable of providing assent. In determining whether children are capable of 
assenting, the IRB shall take into account the ages, maturity, and psychological state of the children 
involved. 
56 Permission from one parent or guardian is acceptable for research covered by §§ 46.404 and 46.405, but 
where research is covered by §§ 46.406 and 46.407 both parents must give their permission unless one 
parent is deceased, unknown, incompetent, or not reasonably available, or when only one parent has legal 
responsibility for the care and custody of the child. See 45 CFR §46.408. 
57 45 CFR §46.404-7. See also Jeffrey P. Burns, Research in Children, 31 CRIT. CARE Med. 2003 No. 3 
(Suppl.) at SI34. 
- 
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who rely on such a distinction."'1 Rather than analyzing the overall risk posed by a research 
protocol, the risk posed by each individual intervention or procedure in the protocol is assessed. 
These risks are weighed against possible benefits caused by those same interventions or 
procedures. This assessment prevents the error of justifying an extremely risky intervention 
simply because it is part of a protocol deemed to have large overall benefits. An important caveat 
to the risk/benefit calculation for each study is that the benefits can only encompass the health 
consequences of the study's interventions and procedures. Economic incentives such as direct 
payments, free medical treatment, free medications or diagnostic tests are not included as 
benefits because using economic incentives in the risk/benefit analysis or including them as 
benefits in the informed consent is viewed as starting a slippery slope toward undue inducement. 
§404: No Greater than Minimal Risk 
The first category of research is that which involves interventions or procedures that pose 
nothing greater than minimal risk to a research subject who may be either a healthy child or a 
child with an illness. For this research, the criteria for approval are essentially the same as those 
required for all human subjects including adults or non-vulnerable populations. The only 
additional requirements for a pediatric population are that the child's assent be obtained (if 
possible) and that a parent or guardian gives permission for the child's participation in the 
study.Because the idea of "minimal risk" is subject to multiple interpretations, the drafters of 
the regulations attempted to clarify to the words by defining that minimal risk "means that the 
risks of harm anticipated in the proposed research are not greater, considering probability and 
magnitude, than those ordinarily encountered in daily life or during the performance of routine 
physical or psychological examination or tests.The idea behind the minimal risk threshold is 
that it is a socially permissible level of risk to which parents would normally permit their 
58 See Levine, supra note 36, at 560 and accompanying text. 
59 45 CFR §46.404 and §46.402 (b) Assent means a child's affirmative agreement to participate in research. 
Mere failure to object should not, absent affirmative agreement, be construed as assent, (c) Permission 
means the agreement of parent(s) or guardian to the participation of their child or ward in research. 
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children to be exposed in non-research settings. The National Commission provided some 
examples of interventions that easily fall within this category: routine immunizations, modest 
changes in diet or schedule, physical examination, obtaining blood and urine specimens, and 
developmental assessments.M It is important to remember that for protocols that fall under this 
category, it does not make any difference whether the intervention has the potential to benefit the 
subject or not, or whether the child is healthy or not. As long as the risk posed by the 
intervention is no more than minimal risk, there are no additional requirements for review and 
acceptability. 
Defining Minimal Risk 
There are several problems with the definition of minimal risk provided in the Code of 
Federal Regulations but many of these can be reconciled by examining the Commission's report 
and the principles of respects for persons, beneficence and justice on which the regulations are 
based. First, the regulations do not explicitly indicate whose daily life should be used as a 
standard, and certainly not all members of the research group are exposed to the same risks of 
harm in their daily lives. For example, a child growing up in extreme poverty may encounter a 
daily risk of malnourishment that is not experienced by her wealthier counterpart. A child 
growing up in a war torn nation, or a country plagued by AIDS will definitely encounter greater 
risks in daily life than a child growing up in a more stable environment.62 Some argue that the 
"daily life" requirement should be based on the average child within that population. Others 
argue that the acceptable risk level should be based on the daily risks encountered by healthy 
children in a stable environment. The definition of minimal risk in the federal regulations differs 
in one important respect to the definition first proposed in the National Commission's 
60 45 CFR §46.102(g) 
61 See Report on Research Involving Children, supra note 41 at xx-xxi. 
62 See, e.g., Burns supra note 57, at S134. Burns asserts: “In particular, if one adopts a relative 
interpretation of minimal risk, then some children whose daily routine exposes them to relatively higher 
risks in theory could also be the subjects of research in which the risk exposure was, therefore, 
proportionally higher than would be approved for a child from a more protected or advantaged 
background.” 
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recommendations. The Commission stated: "Minimal risk is the probability and magnitude of 
physical or psychological harm that is normally encountered in the daily lives, or in the routine 
medical or psychological examination, of healthy children,"63 The Commission's intent was to 
define the minimal risk threshold based on a healthy child but the federal regulations are 
ambiguous. The Commission also provided specific examples of procedures that they considered 
to be no more than minimal risk but these specific examples were excluded from the regulations, 
thereby leaving the acceptability of some of these more common procedures to the individual 
judgment of the IRBs. 
Although the federal regulations do not explicitly define minimal risk to be based on the 
daily risks encountered by healthy children, it is clear that the Commission's report intended it to 
be defined in this absolute way. Consider, for a moment, the possibility that the daily risks in the 
federal regulations are interpreted as being relative and not absolute. Certainly, there are 
children exposed to abnormally high levels of risk, but to use their daily experiences as the 
threshold of daily risk would unjustly subject them to higher risks than other children.'4 This 
type of justification for a high risk protocol is reminiscent of the Willowbrook studies where 
children who were exposed to an abnormally high risk of contracting hepatitis were then given 
hepatitis because it was considered to be a risk to which they were already exposed. 
Undoubtedly, the federal regulations were written to prohibit this type of research, not to protect 
it. Therefore, daily risks, as written in the regulations, must be interpreted as risks that a healthy 
child in a stable environment encounters. 
The National Human Research Protections Advisory Committee (NHRPAC) Children's 
Workgroup was formed in 2000 and was charged with providing advice and recommendations 
on human subjects protection to the Office for Human Research Protections (OHRP). They 
63 See Report on Research Involving Children, supra note 41, at xx (emphasis added). It is interesting to 
note that the Commission offered different definitions of minimal risk in several of its reports in an effort to 
express their view that the threshold should be different for different populations. This subtly was lost 
when the drafters of the federal regulations provided a single definition of minimal risk for all human 
subject populations. (Personal Communication, Robert J. Levine, January 2004). 
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issued a report to clarify the definitions of minimal risk and minor increase over minimal risk. In 
the report they specifically denied that minimal risk should be a variable standard based on a 
particular child's circumstance and defined minimal risk to be the level of risk associated with 
the daily activities of a "normal, healthy, average child.'"* Furthermore, the report states that 
"indexing the definition of minimal risk to the socially allowable risks to which normal, average 
children are exposed routinely should take into account the differing risks experienced by 
children of different ages."* 
Certainly, this argument is not meant to prohibit children exposed to abnormally high 
risks from ever participating in research; it simply asserts that subjecting them to their high 
baseline risks cannot be classified as minimal. The fact that these children face abnormally high 
risks is not a morally relevant distinction that justifies protecting them less when they participate 
in human clinical trials. To use a relative standard for minimal risk would violate the principle of 
justice for these children. They would be subject to an unequal distribution of the burdens of 
research involving human participants because riskier studies could be performed with them 
whereas they could not be performed with healthier children. 
The second difficulty with the definition of minimal risk is that it considers the 
"probability and magnitude" of possible harm, but it does not provide a framework with which 
to judge what are acceptable probabilities and magnitudes of harm. To decide what is an 
appropriately low level of probability of harm or degree of magnitude is not an easy task. The 
evaluation requires careful balancing and normative assessments since sometimes a low 
probability of substantial harm might be approved whereas a high likelihood of a more moderate 
harm may not.h7 Because the federal regulations do not suggest a way to judge acceptable levels 
of harm, the IRBs are left to make the decisions on their own. The federal regulations do not offer 
64 See Loretta M. Kopelman, Children as Research Subjects: A Dilemma, 25 J. OF MED. & PHIL. No. 6, 
745, 754 (2000). 
65 Clarifying Specific Portion of 45 CFR 46 Subpart D that Governs Children’s Research, National Human 
Research Protections Advisory Committee, Children’s Workgroup Report, [hereinafter Workgroup Report] 
(text available at <http://ohrp.osophs.dhhs.gov/nhrpac/documents/nhrpacl6.pdf>. 
66 Id. 
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any examples of acceptable or unacceptable harms as a reference point for the IRBs. Perhaps the 
local IRBs are best suited to make this assessment on a case-by-case basis, but one might also 
argue that leaving too much power in the hands of overburdened IRBs without adequate 
guidance is a recipe for inconsistency and a set up for disaster. 
§405: Interventions with Prospect of Direct Benefit to Subject 
The second category includes procedures or interventions that have the potential to 
benefit the individual subject directly. In these cases, it does not matter if the intervention poses 
greater than minimal risk to the subject and the minimal risk evaluation is not needed in the 
analysis of these cases. Because this class of interventions must have the prospect of directly 
benefiting the subjects, it will generally involve a child who is not the average healthy child in a 
stable environment.'1* In such cases, the research protocol has the added requirements of showing 
that the risk posed to the subjects is justified by the anticipated benefit, and that the anticipated 
benefit is at least as favorable to the subjects as that presented by available alternatives.** 
An example of a research protocol that easily falls into this category is a study with a new 
chemotherapeutic agent for leukemia. The new drug may pose a significant risk to the potential 
subjects, but as long as the anticipated benefits are also high, and the expected benefits from the 
agent are at least as high as the current available alternative medication, then the trial would be 
appropriately approved. Importantly, any control arm of this study would need to receive the 
current available alternative medication and not a placebo in order for the trial to be approved. 
Although it may be subject to more controversy than the above example, there are 
situations when determining the high level of daily risks to which some populations are exposed 
and using that level of risk in a study is absolutely essential to studying potentially beneficial 
67 See Kopelman supra note 64, at 753. 
68 But cf. Bruce Gordon et. al.. The Use of Normal Children as Participants in Research on Therapy, IRB: 
Ethics & human Research, 5-8 (May-June 1996). This study involved using siblings of ill children in a 
protocol that involved more than minimal risk procedures. The healthy siblings were viewed as gaining a 
direct psychological benefit from participating in the research protocol (because they could potentially help 
keep their ill sibling alive) and therefore, were able to participate under §405. 
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interventions for those populations. While justifying higher risks for a specific population may 
tread on dangerous ground, there is a moral imperative to do so because without such research, 
there will be fewer developments in the ways in which those exact same higher risks could be 
lowered. It would not be possible to study a particular risk factor and try to find a way to 
alleviate it in a practical manner unless the protocol continued to expose the population to their 
normal daily risks for the duration of the study. In order for the results of a study to be practically 
applicable to the population, the intervention must be tested within the population's normal 
environment and daily risk exposures. In these cases, the principle of justice demands that 
adequate research studies are carried out with these populations in order to help lower the risks 
to which they are exposed. 
A real-life case example is provided by the placebo-controlled trials of the "short- 
duration" AZT therapy in preventing perinatal transmission of HIV in developing countries. 
Some opponents of the research argued that the research subjects were unjustly treated in that 
they received a sub-standard level of care during that trial. True, the subjects did not receive the 
best proven therapeutic method available in industrialized countries (076 regimen), but the 
interventions they did receive had the possibility of being beneficial in their specific situation. To 
ride an ethical high horse about why research that is not acceptable for a child in America should 
also not be acceptable for a child in a disease-torn country does a disservice to the child who is 
subjected to the increased risks already. That child has the potential to benefit from the research 
far more than the child in America, and the risk/benefit analysis needs to take this into account 
in the determination of what is acceptable research. Levine argues that to use the 076 regimen in 
these countries would have required an almost impossible revision of their perinatal customs 
including requiring women to seek prenatal care much earlier than they are accustomed, using 
intravenous medications, and finding a safe alternative to breast feeding for babies of HIV- 
69 See 45 CFR §46.405. 
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infected mothers in countries with no infant formula and contaminated water supplies." Levine 
asserts: 
In summary, it is clear that the 076 regimen of AZT cannot be 
made available to most HIV-infected pregnant women in the 
resource poor countries now or in the foreseeable future. This is 
the main reason that it is essential to find methods to reduce the 
rate of perinatal transmission of HIV that are within the financial 
reach of the resource poor countries. Finding these methods was 
the primary justification for conducting the clinical trials of the 
short duration regimen of AZT. The cost of the AZT in this 
regimen was about ten percent of that of the 076 regiment. 
Moreover, there was no need for intravenous therapy or 
administration of the drug to the babies. At the time the trials 
began, it seemed likely that two of the countries could afford to 
provide the short duration regimen if it proved effective; there 
was also a commitment from international agencies to assist the 
other resource poor countries in securing and providing the 
drug.71 
Another example provides additional clarity: If a child is already exposed to a 
contaminated water supply and there are no resources to improve the supply, a study to see if 
partially purified water alleviates some disease that is usually caused by the impure water should 
be acceptable.72 Such a study submits the children to a higher level of risk than an average 
healthy child, but it has the potential to benefit the subjects in a way that healthy children would 
not benefit. To expose the children to improperly cooked meat or another type of risk to which 
they are not already exposed would not be permissible, even though it poses a similar level of risk 
as the impure water, because the risk is not something already experienced by the child. 
Furthermore, taking a child with a healthy water supply and submitting her to impure water for 
the purpose of the research would also not be permissible under §405 because she does not gain 
any direct benefit from the intervention. Although this scenario may seem far-fetched because 
pure water is taken for granted in an industrialized country like America, the hypothetical is 
70 See Levine supra note 36, at 563. 
71 Id. See also Council for International Organizations of Medical Sciences, International Ethical 
Guidelines for Biomedical Research Involving Human Subjects, (Geneva 2002). 
72 One might argue that in each of these cases the children are not truly exposed to a risky intervention but 
instead something of potential benefit is withheld from them. The withheld benefit is something to which 
they did not previously have access and will likely not have access to in the future. True, the regulations do 
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analogous to a recent study involving lead abatement interventions to reduce lead poisoning in 
children. 
Grimes v. Kennedy Krieger Institute: §405 Gone Awry ? 
In 1993, the Environmental Protection Agency awarded a research grant to the Kennedy 
Krieger Institute (KKI), a research institution affiliated with Johns Hopkins University, entitled: 
"Evaluation of Efficacy of Residential Lead Based Paint Repair and Maintenance Interventions."71 
The study was designed to compare comprehensive lead paint abatement with less- 
comprehensive repair and maintenance interventions that would possibly be more cost effective. 
There were five arms to the study, three of which were interventions with different levels of lead 
abatement and two of which were controls. Researchers used houses that were built before 1941 
or had documented lead based paint present for the intervention groups. Each of these three 
groups received a different amount of money in either grants or loans for different levels of 
repairs and maintenance aimed at reducing lead within the house. Groups four and five 
consisted of houses that were already lead abated or houses that were built after 1980 when lead 
paint was no longer used. 
The subjects enrolled in the study were the children of the families that rented the homes. 
Some of the children were already living in the homes included in the study, but importantly, 
some of the families moved to the houses during the study because participation in the study was 
what allowed the properties to be on the rental market.4 Investigators recruited families with 
young children to occupy the homes. Parents permitted their children to participate in the study 
and agreed to submit them to as many as eight or nine blood tests within the following two years. 
not specifically address this issue. But, in this hypothetical, one can imagine a scenario where the method 
of partially purifying water exposes the children to an additional degree of risk. 
73 Grimes v. Kennedy Krieger Institute, Inc., 782 A.2d 807, 819 (Md. 2001). See also Hazel Glenn Beh, 
The Role ofIRBs in Protecting Human Subjects: Are We Really Ready to Fix a Broken System? 26 Law & 
and Psychol. Rev. 1,4 (2002). 
74 See Beh supra note 73, at 5-6. Landlords participating in the study attempted to rent to families with 
young children and in return, KKI helped the landlords apply for grants for lead abatement. 
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to allow their homes to be tested for lead periodically over that time period and to answer 
questionnaires/" 
The Johns Hopkins University Joint Committee on Clinical Investigations, the 
institution's IRB, initially questioned whether the use of healthy control subjects in non lead- 
paint homes was permissible under the federal regulations given that there was no real 
therapeutic benefit to these control subjects (and therefore, the intervention could not be 
categorized under §405)."" The IRB therefore suggested that the consent form be changed to 
identify some additional benefits that all subjects would receive by participating in the study." 
The IRB suggested that the consent form indicate that the control group was being studied to 
determine the amount of lead exposure these children would have outside the house, and 
therefore, these children would also receive some benefit from the study interventions. 
Two of the families in the study later sued KKI when their children were found to have 
increased levels of lead. The families alleged that KKI discovered lead hazards in their respective 
homes and, having a duty to notify them, failed to warn in a timely manner or otherwise act to 
prevent the children's exposure to the known presence of lead. Additionally, they alleged that 
they were not fully informed of the risks of the research.s The trial court in Baltimore granted 
summary judgment in favor of KKI on the ground that KKI did not owe a legal duty to the 
plaintiffs to warn them of the presence of lead dust but the appellate court vacated the lower 
court's ruling and remanded for a trial. Although the appellate court determined that KKI may 
have owed a legal duty to the plaintiffs and therefore, the decision could not be made on 
summary judgment, the appellate court overstepped the limited question presented by the case 
and made several statements in its opinion that are simply not in line with a reasonable 
interpretation of the federal regulations. 
75 Id. at 7. 
76 The IRB failed to appreciate that the control arms (houses without lead) did not pose greater than 
minimal risk to the subjects and therefore was justifiable under §404. Furthermore, if all the children are 
viewed as being “at-risk” for lead exposure, then the subjects in the control arms, having been removed 
from lead risks in the home, did benefit from the intervention. See Lainie F. Ross, In Defense of the 
Hopkins Lead Abatement Studies, 30 J.L. Med & ETHICS 50, 52 (2002). 
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From the facts available to the appellate court, it does appear that KKI's protocol violated 
several of the federal regulations as well as basic ethical norms. Some of the more egregious 
errors included: (1) enticing healthy controls to move into lead exposed housing (violation of 
§404 because lead exposure is more than minimal risk79); (2) rephrasing the protocol (at the IRB's 
suggestion) so that healthy controls in groups four and five were supposed to obtain some benefit 
from the interventions even though it seemed unlikely that they were being exposed to lead 
outside the home (this was simply a disingenuous representation of the study); (3) inadequate 
consent forms (violation of requirements for informed consent in §46.116); and (4) a several 
month delay in reporting the lead levels to the families (violation of a promise made by KKI to 
the subjects). Although these violations of the federal regulations and unethical acts can hardly 
be excused, it is important to note that the Grimes Court also erred in several respects.*" 
The Court made the pervasive mistake of classifying the research into "therapeutic" and 
"non-therapeutic" categories and it deemed the research study here to be "non-therapeutic." By 
adopting the "package deal" the court denied that any of the interventions could have a direct 
benefit to any of the subjects. This in fact was not the case. The children who were already living 
in the houses with high lead levels did receive direct benefit by obtaining a degree of lead 
abatement in their houses.*1 The Court stated: "We hold that in Maryland, a parent, appropriate 
relative, or other applicable surrogate, cannot consent to the participation or other person under 
legal disability in nontherapeutic research or studies in which there is any risk of injury or 
damage to the health of the subject." The Court later explained this statement by insisting that it 
77 See Beh supra note 73, at 8-9. 
78 See Grimes, 782 A.2d at 818. 
79 Even if being “at-risk” of lead poisoning qualifies as a “condition or disorder” §406 may have been 
violated because the risk of living in lead contaminated housing may be more than minor increase over 
minimal risk. 
80 See Grimes, 782 A.2d at 860. J. Raker concurred in result only, stating: “I cannot join the majority’s 
sweeping factual determinations that...IRBs are not sufficiently objective to regulate the ethics of 
experimental research; that it is never in the best interest of any child to be placed in a nontherapeutic 
research study that might be hazardous to the child’s health; that there was no therapeutic value of the 
research for the child subjects involved; that the research did not comply with applicable regulations; or 
that there was more than a minimal risk involved in this study.” 
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meant "minimal risk" when it stated "any risk,"82 but even given this clarification, the Court 
seems to permit only §404 research and completely deny §405 research primarily because it fails 
to recognize that the use of the nontherapeutic label causes it to reject the entire protocol instead 
of weighing the interventions' potential benefits against the risks. The Court disregards that it is 
permissible to approve nonbeneficial procedures according to §405. 
In other words, if the protocol had included only houses that already had children living 
in them, every child in the three intervention groups would have received some benefit from 
being part of the trial because their lead exposure was likely to decrease, and therefore, the trial 
should be deemed acceptable under §405. Furthermore, the children in groups four and five 
would not be subjected to the risk of lead and only required to have periodic venipunctures, an 
intervention while not directly beneficial, poses only minimal risk and falls under the category of 
procedures that are approvable under §404. From the statements made by the Grimes Court, 
however, it appears that they would not accept even this limited study because the continued 
exposure to some lead for the intervention groups is more than a minimal risk. One might object 
to this more limited study because the children in the intervention groups are not receiving fully 
lead abated houses, but similar to the short-course AZT trials, this population of children does 
not have realistic access to fully lead abated houses, so certainly to help them a little is better than 
no help at all. Unfortunately, the Grimes Court overstepped the limited question presented to it 
and its opinion, taken to its fullest, would not permit even this hypothetical study where no 
children are actively recruited to live in lead contaminated houses.81 
The Grimes opinion should raise warning bells that if the federal regulations are not 
explicated further, either in the federal regulations themselves, or by an authoritative 
81 In fact, the partial lead abatement interventions were so effective that the program has been replicated in 
13 other cities. See Robert M. Nelson, Nontherapeutic Research, Minimal Risk, and the Kennedy Krieger 
Lead Abatement Study, IRB: ETHICS & HUMAN RESEARCH, 7 (Nov-Dec 2001). 
82 See Ross, supra note 76, at 51. 
83 This is an important distinction that sets it apart from the Willowbrook studies. Even if the prevalence of 
lead-tainted houses in the Baltimore area were 85%, it would not be permissible to actively rent previously 
empty houses in the study to families with children. This is analogous to the situation in Willowbrook 
where the children living in the house had an 85% risk of contracting hepatitis. The high baseline risk does 
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governmental body, mistakes in interpretation will lead to results not intended by the National 
Commission or the drafters of the regulations. 
§406: Interventions with No Prospect of Direct Benefit to Subject 
The third category involves interventions or procedures with no prospect of direct 
benefit to the subject. For these types of studies, the intervention must present only a minor 
increase over minimal risk to the subject, and the study must be likely to yield knowledge about 
the child's disorder or condition that is of vital importance for the understanding or amelioration 
of the disorder or condition. Furthermore, the intervention or procedure must present 
experiences to the subjects that are reasonably commensurate with those experiences inherent to 
their actual or expected medical, dental, psychological, social or educational situations.^ The 
commensurability requirement exists because children who have had a particular intervention 
previously are better able to understand what is being asked of them and therefore, their assent 
to participate in the study will be better informed."’ The questions of what constitutes a "minor 
increase" above minimal risk, and what is meant by "disorder or condition" and "reasonably 
commensurate" have produced considerable disagreement and serve as another source of 
differing interpretations of the regulations. 
A research protocol that might fall within this category is a trial that takes a child with 
leukemia and subjects her to one additional bone marrow aspirate in order to obtain information 
about the disease course, but information that is not intended to benefit this particular child. It is 
imaginable that the child with leukemia has already had a bone marrow aspirate and that 
another aspirate would be reasonably commensurate with her actual experience so that if she 
assents to participate, her assent is more informed than a child who has never experienced a bone 
marrow aspirate. Furthermore, it is imaginable that such a research study could be designed to 
not give the researchers the right to turn a high risk into a definite risk (either living in a lead contaminated 
house or contracting hepatitis) for a particular child. 
84 See 45 CFR §46.406. 
83 Levine, supra note 5, at 248. 
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yield generalizable knowledge about leukemia that is of vital importance for its amelioration, and 
therefore such a trial would fulfill the requirements set by §406. In this hypothetical case, one 
additional bone marrow aspirate is viewed as only a minor increase over minimal risk, but what 
if the protocol called for two? Three? Ten? When is the threshold exceeded? Some might argue 
that it is not possible to set a threshold - that it is an instinctual "gut feeling" that causes 
reviewers to know when the limit has been exceeded. But surely this type of "I know it when I 
see it" standard that the Supreme Court has used for recognizing pornography cannot be 
invoked when errors in judgment potentially expose children to real danger.3'’ IRBs would be 
hard pressed to find a public willing to accept such a subjective interpretation of §406. 
Defining Minor Increase 
The NHRPAC Children's Workgroup Report provided some insight into the definition of 
minor increase over minimal risk. The group concluded that minimal risk itself should be an 
absolute standard but that "minor increase over minimal risk" is a relative standard. They 
acknowledged that the concept of commensurability is crucial to allow the child and parents to 
have a point of reference from which to make their decision about participation. The Workgroup 
report included lists of specific interventions and how they thought those interventions should be 
classified. (See Tables 3 and 4.) Nevertheless, these recommendations are not universally agreed 
upon and local IRBs will differ on their decisions of whether a particular research protocol is 
acceptable or not. Some examples of what has been approved by Yale's IRB as presenting minor 
increases above minimal risk include bone marrow aspirations in children with leukemia, single 
additional spinal taps in adolescents who have already had at least one for a neurological 
disorder, and administration of yohimbine in order to gain information about the pathogenesis of 
a neurological disorder. This IRB rejected a proposal to do left heart catheterizations on children 
at risk for the development of cardiac hemosiderosis.3' 
86 See Jacobellis v. Ohio, 378 U.S. 184, 197 (1964) (6-3 decision) (Stewart, J., concurring). 
07 0 
Levine, supra note 5, at 249. 
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Table 3: Common Procedures and Category of Risk33 
Procedure* Minimal 
Risk 
Minor Increase 
Over Minimal 
More than a Minor 
Increase over 
Minimal 
Routine history taking X 
Venipuncture/fingerstick/heelstick X 
Urine collection via bag X 
Urine collection via catheter X 
Urine collection via suprapubic tap X 
Chest xray X 
Bone density test X 
Wrist xray for bone age X 
Lumbar puncture X 
Collection of saliva X 
Collection of small sample of hair X 
Vision testing X 
Hearing testing X 
Complete neurological exam X 
Oral glucose tolerance test X 
Skin punch biopsy w/topical pain 
relief 
X 
Bone marrow aspirate w/topical pain 
relief 
X 
Organ biopsy X 
Standard psychological tests X 
Classroom observation X 
* The category of risk is for a single procedure. Multiple or repetitive procedures are likely to 
affect the level of risk. 
88 Workgroup Report, supra note 65. 
' 
. 
33 
Table 4: Interpreting Level of Risk in Common Procedures89 
Procedure Determinants of Level of Risk 
Indwelling heparin lock catheter The level of risk may range from minimal to more than a 
minor increase over minimal depending on: age of the child, 
length of time catheter will be in place, number and volume 
of samples, and setting of the research 
Single SC or IM injection The level of risk of a single injection may range from minimal 
to more than a minor increase over minimal depending on 
the substance injected 
Nasogastric tube insertion Generally minor increase over minimal risk but should be 
commensurate with prior experience of the child in order to 
provide adequate assent and permission 
Small amount of additional 
tissue obtained at surgery 
Generally minor increase over minimal risk but must take 
into account any increased operative time, the specific organ 
or tissue, and the likelihood of bleeding and infection 
MRI If no sedation - generally minimal 
If procedural sedation - generally minor increase over 
minimal. Intubation in the appropriate setting may decrease 
potential risks for certain children and its possible use should 
be considered on a case by case and proposal by proposal 
basis. 
Psychological test 
/survey/ interview/observation 
Generally minimal if performed under standardized 
conditions but the level of risk may increase depending on 
the sensitive nature of questions, the possibility to trigger 
unpleasant memories or emotions, and the length of the 
instrument or observation 
One of the problems with the §406 requirements is that it is very difficult, if not 
impossible, to generate any control data with healthy children for these types of studies. In the 
leukemia example above, it would not be permissible to subject a healthy child to a bone marrow 
aspirate because it is a procedure that is not reasonably commensurate with the child's actual or 
expected situation. Furthermore, §406 presupposes a clear line between a child with a disease 
and a child who is healthy. As was demonstrated through the examples for §405 research, the 
line is not always well demarcated because the more "at-risk" a population is, the more it may be 
considered unhealthy. In fact, the NHRPAC Workgroup defined the concept of "disorder or 
condition" rather broadly: 
We interpret the concept of disorder or condition as relating to a 
specific characteristic which describes a group of children, a 
physical, social, psychological, or neuro-developmental 
condition affecting children, or the risk of certain children 
89 Id. 
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developing a disease in the future based on diagnostic testing or 
physical examination. Thus, for example, prematurity, infancy, 
adolescence, poverty, living in a compromised physical 
environment, institutionalization, or having a genetic 
predisposition to future illness are some disorders or conditions 
of children that can, under the appropriate circumstances, 
warrant permissible research that presents levels of risks that are 
a minor increase over minimal without the prospect of direct 
benefit."’ 
The NHRPAC definition, therefore, seems to classify the risk of developing a disease as a 
disorder and therefore broadens this category of research widely. One might wonder, then, 
would the NHRPAC Workgroup permit children in the lead abatement study who have normal 
lead levels but are at risk for developing lead poisoning simply because they lived in an area of 
Baltimore where the prevalence of living in a lead-tainted home is very high, to be enrolled in a 
study that presented a minor increase over minimal risk without any intervention that could 
provide direct benefit to the subjects (i.e. the recruitment of children from the area to move into 
the homes participating in the study)? The Workgroup provided an example of children who 
have a predisposition to diabetes because they are obese being enrolled in a study that used 
various procedures to assess insulin resistance." Although the risks posed by the interventions 
would not be minimal because they are greater than those risks normal, healthy, average children 
encounter, the study could be approved under §406 because the interventions posed only a minor 
increase over minimal risk, the study would be likely to yield generalizable knowledge of vital 
importance about the development of diabetes or pathophysiology of obesity, the interventions 
performed were commensurate with the expected experience of the subjects, and the site for the 
study and skill of the investigator were appropriate. The NHRPAC Workgroup meant to define 
disorder or condition more concretely, but their example reveals how the line between healthy 
children and children with disorders or conditions is very difficult to draw. For example, are 
children with a body mass index of 29.9 at-risk for diabetes and therefore qualify as having a 
90 Id. 
91 But cf infra notes 93-95 and accompanying text. 
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"condition"?v2 What definition of obesity should be used? When do healthy populations become 
"at-risk"? The NHRPAC Workgroup's expansive definition of condition or disorder will 
definitely engender debate, but certainly such a definition does allow access to more control data 
as the "at-risk" children can serve as "control" subjects in many studies. It is important to 
recognize though, that as the NHRPAC Workgroup's definition makes research using "control" 
subjects easier, it does so at the expense of the commensurability safeguard, because these 
children are less likely to fully understand whether the intervention in the protocol is similar to 
an actual or expected situation. 
Stephanie Amiel, a Yale pediatric endocrinologist studying diabetes, completed a study 
where "normal controls" were admitted for a 48-hour hospital stay in order to allow a 24-hour 
blood hormone level profile through an intravenous cannula, plus a 4-hour hormone sensitivity 
test through an additional intravenous cannula.11 This study could not be justified as presenting 
no more than minimal risk because the psychological effects of a two-day hospital stay were 
unknown.4 The "normal controls" were actually siblings of diabetic children and were thus 
judged to have a "condition or disorder" thereby permitting review under §406. The Yale IRB 
approved the study under §406 because it presented only a minor increase above minimal risk. 
In retrospect, the only harm actually suffered by the control subjects seems to have been 
uncomfortable IV sites and boredom, so perhaps the study could have in fact been approved 
under §404 as causing no more than minimal risk, but at the time approval was sought the risks 
could not have been so easily calculated. 
In contrast, the National Institute of Child Health and Human Development (NICHD), 
part of the National Institutes of Health (NIH), began a study to determine population 
differences in insulin sensitivity, resting energy expenditure, and body composition of obese 
children and children of obese parents in 1996 which was subsequently terminated by the OHRP 
92 The current definition for obesity is a body mass index greater than 30. A body mass index between 25.0 
and 29.9 is considered overweight. 
93 See Stephanie A. Amiel, Pediatric Research on Diabetes: The Problem of Hospitalizing Youthful 
Subjects, IRB: A REVIEW OF Human SUBJECTS RESEARCH, 4-5 (Jan-Feb 1985). 
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in 2000J The trial had enrolled over 190 children aged 6 to 10 before it was terminated. The 
investigators had planned to follow the children for 15 years and collect blood samples, 
radiographs and magnetic resonance imaging scans all of which were considered to be minimal 
risk by the original review board that approved the study. Four years later, however, the OHRP 
stated that the interventions posed more than minimal risk'h and did not present the prospect of 
direct benefit to the subjects and therefore could not be approved under §404 or §405 
respectively. Furthermore, it concluded that "these [non-obese healthy children] do not have a 
disease or condition," many of the interventions and procedures were not reasonably 
commensurate with those inherent in their actual or expected situations, and the risks exceeded a 
minor increase over minimal risk, therefore the study could not be approved under §406 either. 
The OFIRP recommended that §407 approval be sought and later terminated the trial 77 
The differences between the Amiel study and NICHD study seem slight, yet the 
outcomes are quite dissimilar. Why do the siblings of diabetic children qualify as having a 
"disease or condition" (and therefore obtain §406 review) but the non-obese children of obese 
parents do not? The siblings of the diabetic patients have a higher risk of developing diabetes 
than the general population, but the same could be argued for the non-obese children. Did the 
Yale IRB or the OHRP look at empiric evidence to determine how "at-risk" these children were in 
their determination of what qualifies as a "condition or disorder"? It seems unlikely given that it 
is questionable whether such data exist. Neither the Yale IRB, nor the OHRP elucidated the 
definition of "disease or condition" on which they relied, yet the difference in the outcomes 
94 Levine, supra note 5, at 249. 
95 See Department of Health and Human Services, Office for Human Research Protections, OHRP 
Compliance Activities, Determination Letters, (November 3, 2000, January 17, 2001 and October 30, 2002) 
[hereinafter Determination Letters] (text available at: 
<http://ohrp.osophs.dhhs.gov/detrm_letrs/lindex.htm>). 
96 The specific intervention that posed more than minimal risk was a “clamp” study that required an 
overnight stay in the hospital with the insertion of two intravenous catheters so that insulin and sugar could 
be infused while taking blood samples. The study would manipulate each child’s blood sugar between 80- 
200 mg/dL and measure the child’s response. See Eliot Marshall, Enforcers Halt NIH Study Called Less 
Risky than Outdoor Play, 290 SCIENCE 1281 (2000). 
97 See Determination Letter supra note 95, (November 3, 2000). 
■ 
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hinges on these words.'"* Once again, it is obvious that reasonable people can and do interpret the 
federal regulations differently and create drastically different end results. 
§407: Research Not Otherwise Approvable 
Finally, the last category outlined in Subpart D involves research that would not be 
approvable under any of the aforementioned categories. In such cases, if the IRB finds that the 
research presents a "reasonable opportunity to further understanding, prevention, or alleviation 
of a serious problem affecting the health or welfare of children," then the Secretary of the DHHS 
may consult with a panel of experts, provide an opportunity for public review and comment, and 
then possibly approve the research.^ The Secretary can find the protocol acceptable by either 
finding that the research actually does satisfy the conditions of §§404, 405, or 406, of that the 
research (1) presents a reasonable opportunity to further the understanding, prevention, or 
alleviation of a serious problem affecting the health or welfare of children; (2) will be conducted 
in accordance with sound ethical principles; and (3) adequate provisions are made for soliciting 
the assent of children and the permission of their parents or guardians as set forth in § 46.408. 
Although this category has been used to permit research with children infrequently, the OHRP 
lists six protocols as currently under §407 review.1'"’ 
In 1989, Prentice et al. published a description of a case that could not be approved under 
§§404, 405 and 406, and which also was not suitable for §407.101 The protocol was designed, in 
part, to determine whether biosynthetic growth hormone could promote linear growth in 
children suffering from Turner Syndrome. The control arm of the study was to receive placebo 
injections three times per week, plus routine blood and urine exams, and radiographs of the 
hands and wrists every six months to measure bone age. The multiple injections each week and 
98 Although one could argue that even if the non-obese children were said to have a “condition or disorder” 
the interventions posed more than a minor increase over minimal risk and still would not meet the 
requirements of §406. 
99 45 CFR §46.407. 
100 See OHRP web site: <http://ohrp.osophs.dhhs.gov/cpanl.htm> (last visited Jan 30, 2004). 
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the radiological examinations were judged to present more than minimal risk to the subjects, so 
the protocol could not meet §404 approval. Furthermore, there was no firm evidence to support 
the possibility that the placebo group would receive direct benefit from the injections under the 
hypothesis that stress induces the release of natural growth hormone, so the protocol could not 
satisfy §405. The protocol did not meet §406 approval because the fact that the placebo group 
would miss the opportunity to be treated with available alternatives such as different types of 
biosynthetic growth hormone, estrogens or androgens posed more than a minor increase over 
minimal risk; the multiple injections over 18-months was not commensurate with the actual or 
expected medical treatment of a patient with Turner syndrome; and the research would not yield 
generalizable knowledge about Turner that is of vital importance for developing methods of 
treatment because there was no evidence to show that the drug being tested would be any better 
than another biosynthetic drug already being studied for the same purpose. Finally, the IRB 
decided that the protocol did not even qualify for §407 review because they did not think short 
stature was a "serious" enough condition to warrant attempting to get §407 approval.1112 
Interestingly, several years later, similar studies involving the use of growth hormone in children 
with Turner syndrome or idiopathic short stature were presented to an expert panel for §407 
review.1111 The studies were designed as a double-blind randomized control with half the children 
receiving hGH and the other half receiving placebo injections three times a week for four to seven 
years. Although the nine-member panel disagreed about the risks involved with the study, in the 
end, there was only one member of the panel who thought the study could not be justified."’ The 
differences in the study described by Prentice and these more recent studies seem slight, yet the 
latter was permitted under §407 review and the earlier one was not even able to receive §407 
review. There may have been evolving thought over what constitutes a "serious" problem, but 
101 See Ernest D. Prentice et a!., Can Children be Enrolled in a Placebo-Controlled Randomized Clinical 
Trial of Synthetic Growth Hormone? IRB: ETHICS & HUMAN RESEARCH, 6-10 (Jan-Feb 1989). 
102 Id. at 9. 
10'1 See Kopelman supra note 64, at 755. Importantly, hGH was already the standard of care for Turner 
Syndrome, 
104 Id. Kopelman served as one of the co-chairs of the review panel and was the only dissenting member. 
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the evidence once again points to the fact that reasonable people serving on different IRBs, facing 
similar protocols, can reach very different results.1"" 
An example of a study recently approved under §407 was a protocol entitled: Precursors 
to Diabetes in Japanese American Youth.1"" The study was to enroll 300 children of Japanese 
ancestry and 150 Caucasian children to undergo several routine examinations plus blood draw 
by venipuncture, intravenous glucose tolerance test, measurement of body composition by DEXA 
and intra-abdominal fat determination by MRI. None of the interventions had the prospect of 
direct benefit to the children, and several of these interventions were thought to involve more 
than minimal risk. Nevertheless, the majority of the reviewing experts found that the study 
could be approved under §407 pending that the protocol and consent forms be modified to 
further reduce the risks to the subjects. The experts found that the study could be approved 
because it presented a reasonable opportunity to understand, prevent, or alleviate a serious 
problem affecting the health and welfare of children." 
Some argue that this last category of research should be proscribed altogether. Lainie 
Friedman Ross, asserts that research in this category is entirely immoral and that "the decision to 
balance the well-being of a particular child against the possibility of significant societal benefit is 
a utilitarian calculus which fails to respect the developing personhood of the individual child."108 
Ross, however, is too quick to equate a utilitarian analysis with evil when, in fact, most research 
ethics entails ethical justification according to a utilitarian analysis. It is equally possible to 
imagine a child who wants to participate in a research trial that has no component which is 
physically beneficial to him, but one where his psychological well-being is better off because his 
ICb For an interesting discussion of whether a similar trial is ethically permissible involving children with 
very short stature and not Turner Syndrome, see also Carol A. Tauer, The NIH Trials of Growth Hormone 
for Short Stature, IRB: A REVIEW OF HUMAN SUBJECTS RESEARCH, 1-9 (May-June 1994). 
106 J Report on Expert Panel Review Under Subpart D of 45 CFR 46: Precursors to Diabetes in Japanese 
American Youth, (text available at <http://ohrp.osophs.dhhs.gov/pdjay/expert.htm>) (August 13, 2001). 
107 This reasoning implies that the NICHD study would have received §407 approval as well. See supra 
note 95 and accompanying text. 
108 Lainie F. Ross, Children as Research Subjects: A Proposal to Revise the Current Federal Regulations 
Using a Moral Framework, 8 STAN. L. & POL'Y Rev. 159 at 167 (1997). 
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participation in a study may help alleviate a serious problem affecting children.11'1' To prevent 
such a child from participating in a trial may just as easily fail to respect that child's developing 
personhood. The onus is on the researcher to carefully assess whether the benefits to the child 
outweigh the risks, but the lack of physical benefits should not preclude this analysis. For 
example, a trial that involves multiple daily painful procedures for the healthy control group but 
has the potential benefit of alleviating a severe illness for the children in the intervention arms 
may be considered by a healthy child to be a worthwhile sacrifice to make for the benefit of 
others. A utilitarian calculus can just as easily take this into account and conclude that §407 
offers reasonable safeguards for the welfare of children in these studies. 
By devising four categories of risk, the federal regulations sought to provide a level of 
protection for children that is proportionate to the level of risk to which they are exposed. 
Nevertheless, although the regulations seek to provide guidance to IRBs about the acceptability 
of research protocols, the language used in the regulations including "minor increase," 
"reasonably commensurate," "disorder or condition," and "serious problem," are sufficiently 
vague so as to create a battleground over how to define these terms. Even the relatively well- 
defined term of "minimal risk" lends itself to multiple interpretations. Although some of these 
words reach consensus meanings eventually, not all have done so. The definitional ambiguities 
leave an incredible amount of power in the hands of the IRBs. How can we ensure IRBs will 
apply consistent interpretations of the definitions and generate results that reflect the 
commitment to the principles of respect for persons, beneficence and justice? How can courts be 
better informed when facing cases involving children as research subjects so that they do not 
commit the same mistakes the Grimes Court made and produce large discrepancies between IRB 
decisions and court decisions? One possible mechanism for improvement is to restructure the 
institutional review board system. 
!09 This very argument has been used to permit children to donate kidneys to their siblings or undergo bone 
marrow transplant. 
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Part IV: Recommendations for Change 
Disagreements over which interventions pose minimal risk or minor increase over 
minimal risk exist among experts in the field and among members of IRBs. In 1981, empirical 
work by Janofsky and Starfield found significant differences among pediatric experts about how 
to assess the risks of a venous blood draw, arterial puncture and gastric and intestinal 
intubation.* 11" They concluded that the variability in risk assessment by those surveyed suggested 
that their judgments were based on an inadequate body of knowledge.111 In 1982, Goldman and 
Katz published a controversial study of IRBs that concluded that there were significant 
inconsistencies in the application of the federal regulations among many IRBs and that there were 
inconsistencies in the application of ethical, methodological, and informed-consent standards 
within individuals IRBs.112 The researchers gave three imperfect protocols to different IRBs to 
determine whether the boards would identify the ethical, methodological and consent form flaws 
and how they would address these defects. Goldman and Katz reported that IRBs neglected to 
make the appropriate objections to the protocols and that there were internal inconsistencies that 
indicated failures of the individual IRBs. Levine responded to the study by explaining why the 
Goldman-Katz protocols may have received substandard review compared to most of the 
protocols presented to the Yale IRB.111 He reported that the Goldman-Katz protocols did not 
make proper use of the primary reviewer system upon which Yale's system relies. Furthermore, 
the protocols did not go through a second review after initial revisions were recommended, 
thereby eliminating the opportunity to identify additional problems with the protocols. 
Additionally, Goldman and Katz did not recognize some of the ethical objections made by the 
110 Jeffrey Janofsky & Barbara Starfield. Assessment of Risk in Research on Children, 98 J. OF PEDIATRICS, 
No. 5, 842-846(1981). 
111 See id. at 845. 
112 See Jerry Goldman & Martin D. Katz, Inconsistency and Institutional Review Boards, 248 J. Am. Med. 
Ass’n, No. 2, 197(1982). 
113 See Robert J. Levine, Inconsistency and IRBs: Flaws in the Goldman-Katz Study, IRB: A REVIEW OF 
Human Subjects Research, 4-8 (Jan-Feb 1984). 
' 
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Yale IRB and report them correctly.114 Given Levine's critique, one could assume that similar 
types of problems may have occurred with the other IRBs that Goldman and Katz investigated. 
Although the Goldman and Katz study definitely had flaws, there is no denying that 
different IRBs do not always come to the same conclusion about the acceptability of a study.1" 
Furthermore, as the discussion of words such as minimal risk, minor increase over minimal risk 
and disease or condition in Part III reflects, IRBs continue to interpret these concepts differently 
because they are difficult concepts from the outset. Even though the federal regulations attempt 
to divide research protocols into four categories of risk and require additional protections for 
children as the risks increase, the regulations obviously have not created a simple framework that 
will always consistently be applied among different IRBs and within any particular IRB. While 
perfect consistency may be an unattainable goal, given the importance of protecting human 
subjects equally, it is certainly a defensible goal. 
The NHRPAC's Children's Working Group recognized several problems present with 
the interpretation of the current regulations governing clinical research involving children. The 
group, however, concluded that the regulations do not need revision, but rather require 
clarification. The group is currently soliciting members of research institutions to submit 
examples of research protocol that would be approved under §§404, 405 and 406.116 They plan to 
make the report widely available to other advisory committees currently considering the issue of 
protection for children in research. Although the Working Group efforts should be applauded, 
their report is unlikely to provide long-term solutions to the problems of variable interpretation 
of words and inconsistent application of the regulations because it is difficult to anticipate the 
ethical problems that future protocols will pose. 
114 See id. See also Gregory J. Hayes et al., A Survey of University Institutional Review Boards: 
Characteristics, Policies, and Procedures, IRB: A Review OF Human SUBJECTS RESEARCH (May-June 
1995). Hayes points to several problems with IRBs including lack of membership diversity, inadequate 
expertise, observer drift, lack of an evaluation process and groupthink. 
115 See supra discussions of Amiel and NICHD studies at p.35 and human growth hormone studies at p. 37. 
116 See The Social and Behavioral Sciences Working Group on Human Research Protections web site at: 
<http://www.aera.net/humansubjects/Posting-Children.pdf>. 
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The current system relies heavily on IRBs to perform efficiently and appropriately. IRBs 
are required to review fundable federal grant proposals involving human subjects and all FDA 
regulated research as well as most other research involving human subjects to the extent 
specified in their institutions' Federal Wide Assusrances. Additionally, IRBs must determine 
adequacy of consent forms and conduct at least annual review of ongoing studies. Some have 
argued that the increasing number and complexity of multicentered randomized clinical trials 
overtax IRBs.117 Others have argued that the real problem is that IRBs are weighed down with 
tedious, low-yield, time-consuming tasks.118 Further criticism of the entire system is that the 
dependence on IRBs yields inconsistence results. 
Mashaw wrote that if an IRB is to "do its core job well, we must live with its inevitable 
incompetence at other tasks. Moreover, we must also live with the rather vague regulatory 
standards and with the continuing inability of the Federal funding agencies to know for sure 
whether IRBs are functioning effectively."117 True, maybe the current scheme imposes too many 
demands on the local IRBs, but instead of accepting the weaknesses in the system, perhaps a 
different system is needed. 
One way to establish clarification of the current regulations and create a system that will 
encourage greater consistency while maintaining some flexibility is to change the review board 
system. A restructured system that distributes duties within a regulatory hierarchy will help 
solve the current problems and, perhaps more importantly, provide a long-term solution by 
establishing a permanent process by which to address new issues as they arise. Although the 
proposal that follows discusses only the federal regulations involving children, one might 
imagine a system where all protocols involving human subjects are able to use the restructured 
review board system. 
117 See William J. Burman et al.. Breaking the Camel’s Back: Multicenter Clinical Trials and Local 
Institutional Review Boards, 134 Ann. OF INTERNAL Med. No. 2 152, 155 (2001). 
118 See Robert J. Levine, Institutional Review Boards: A Crisis in Confidence, 134 Ann. OF INTERNAL Med. 
No. 2 161 (2001). 
119 See Levine supra note 5, at 327, quoting from J.L. Mashaw, Thinking About Institutional Review 
Boards. In: The Presidential Commission for the Study of Ethical Problems in Medicine and Biomedical 
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A Proposal to Restructure the Review Board System: 
A new review board system will preserve the local IRBs, create twelve Regional Review 
Boards (RRBs) and one National Review Board (NRB). The system will use a hierarchical 
structure that is similar to the federal court system. (See Figure 1.) The structure will include 
local IRBs with their current membership, but their duties will be slightly different. The local 
IRBs will continue to review protocols as required by §46.108 and §46.109, except that under 
certain circumstances, they will have the discretion or the requirement of forwarding protocols to 
their RRB. Although minimal risk protocols are generally easy to spot, those protocols that do 
not clearly fall under §404 review can be forwarded, at the discretion of the local IRB, for regional 
review. Furthermore, protocols that are reviewed under §405 or §406 and are contentious with 
regard to what level of risk exists, must be forwarded to the RRB. Those that are contentious will 
include protocols where there is definite disagreement between IRB members over how to 
classify the risks of the interventions and procedures, and where no precedent exists for 
approving or rejecting such a protocol. The precedent may exist from a protocol reviewed by 
that same local IRB, the appropriate RRB or the NRB. These rules regarding what may be 
submitted for regional review should appropriately limit the number of cases that are sent to the 
RRB, but still allow a sufficient number to pass to the RRB so that it gains experience addressing 
these more difficult cases. 
Finally, protocols that are determined to fall under §407 review and previously required 
the assembly of an expert panel, will now receive automatic NRB review. §407 will be amended 
to reflect that instead of asking the Secretary to consult with a panel of experts, the IRB will ask 
the Secretary to consult with the NRB to make a decision based on the remaining requirements of 
§407. The NRB will function as the expert panel in these cases. 
Research: Whistleblowing in Biomedical Research: Policies and Procedures for Responding to Reports of 
Misconduct, p. 3-22. U.S. Gov. Printing Office, Stock No. 040-000-00458-1, Washington, DC 1982. 
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Figure 1: Analogous Structure of Federal Courts and Proposed Review Boards 
The intention behind enabling local IRBs to forward protocols to the RRBs is to 1) remove 
the responsibility of defining ambiguous terms from the IRBs who have minimal time to devote 
to any one protocol; 2) encourage greater consistency between local IRBs in how they apply the 
federal regulations by mandating that they look to precedents (including precedents from the 
regional and national levels) when making decisions; 3) reduce the likelihood of conflicts of 
interest and or bias that can exist when local IRBs review their colleagues' proposals; and 4) 
perhaps, decrease some of the time that local IRB members devote to reviewing difficult 
protocols. Accusations have been made that local IRB members often do not fully understand the 
nuances between the words in the regulations and therefore, do not appropriately apply the 
regulations.1'" This new regulatory structure removes the more sophisticated analyses from the 
purview of local IRB members who, even if they have a genuine interest in research ethics, may 
not have the time or desire for appropriate training or education in the field, and places them in 
the hands of a more qualified body. 
I“° See Bette-Jane Crigger, What Does it Mean to “Review" a Protocol? Johns Hopkins & OHRP, IRB: A 
Review of Human Subjects Research, 13-15 (July-Aug 2001). During the OHRP investigation of the 
IRB system at Johns Hopkins University, the OHRP concluded that Hopkins failed to protect human 
subjects appropriately after the death of a healthy 24-year-old woman in research designed to study asthma 
physiology. OHRP concluded that the large volume of research overburdened IRB members and chairs 
and that members did not sufficiently understand the federal regulations. 
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In addition, investigators whose applications are denied at the local level will be 
permitted to appeal their protocols to the RRB for reconsideration. Because the RRB will meet 
less frequently than the local IRB and there will likely be a delay before a decision is made, most 
investigators will be dissuaded from appealing their protocol unless they truly think it deserves 
another review. Given the current lack of the need for an appeals process at some institutions, it 
seems unlikely that this appellate function of the RRBs will be used very often, but it is still 
valuable for it to exist.121 Finally, the local IRBs should continue to work closely with local 
investigators, remain familiar with the local institutions, and educate themselves and others 
regarding research ethics. The local IRBs unmatched experience with reviewing a large volume of 
protocols will enable them to identify ambiguities in the regulations and problems with their 
application best and send protocols exemplifying these problems to the RRB level. 
The RRBs will be organized and tailored to fit their charge. There will be 12 regional 
RRBs, each one serving a specific geographical jurisdiction, analogous to the federal Circuit 
Courts, and they should meet at least once a month. Membership of an RRB should consist of 
representatives from its local IRB constituents, but given the large number of local IRBs, a 
revolving membership is needed to ensure adequate representation but manageable meetings 
and discussions. Each IRB may nominate one member to serve on the RRB. The RRB Chair will 
review all those nominated and assemble a board of 20-30 members that best reflect the 
constituents and meets the requirements of §46.107. Furthermore, no more than one member 
from any local IRB may serve on the RRB. Membership should not exceed three years, and a 
revolving membership should create a system that allows different local IRBs have a turn serving 
on the RRB. Large academic institutions with large numbers of research studies under review, 
however, may end up serving on their RRB continually, but a different representative from the 
institution should serve as the RRB member. 
121 See Levine, supra note 5, at 341, for a report that an appeals process at Yale ceased to exist because 
there were no requests for an appeal for over 15 years. 
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In addition, there should be at least one member of the RRB with full-time duties. This 
member will be responsible for writing a synopsis of the discussion and conclusion reached for 
the cases presented. The intention is that this will include a more detailed summary than just 
minutes of the meeting. It will be a sufficiently detailed synopsis that can serve as a precedent to 
which local IRBs can turn for future guidance on similar issues. These case summaries should be 
published and catalogued in a searchable database for easy access by IRBs, the NRB and 
members of the public. 
The RRB members will assume a higher degree of responsibility in understanding the 
federal regulations and research ethics. To that end, members will be required to undergo a well- 
structured, high-quality educational course. This is not to say that the local IRB members are 
absolved of the duty to be well-informed of the federal regulations and research ethics, but rather 
that a high-quality, time-consuming educational system will be easier to initiate with a smaller 
number of self-selected individuals who have a veritable interest in research ethics.122 Perhaps, 
such an education system could later be extended to local IRB members. 
The charge to the RRBs will be to not only review the protocols sent by the local IRBs, but 
to clearly summarize the way in which they choose to define certain terms in the regulations. In 
other words, if the RRB decides that the child of obese parents qualifies as having a "condition" 
the RRB must identify how they reached that conclusion. If they relied on specific data to make a 
conclusion, that should be identified as well. Furthermore, they must be bound by their own 
precedents and those set by the NRB. This will ensure that their decisions are internally 
consistent and ideally, promote consistency between the various IRBs within their jurisdiction. 
Because the members of the RRB will have a greater understanding of research ethics and the 
regulatory guidelines due to their education on the subjects, they will be in a better position to 
review these more difficult protocols. Furthermore, because they will not oversee the expedited 
review protocols or the minimal risk protocols, they should, ideally, have more time to dedicate 
122 Cf Levine, supra note 118, at 162. Levine calls for an education system for all IRB staff and members. 
He further reflects on adding an accreditation system for IRBs and a certification system for IRB staff. 
. 
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to each of the protocols that comes before them for review. Finally, when the RRB members are 
unable to reach a consensus decision on a particular protocol they will be permitted to send up to 
20% of their protocols to the NRB. 
Structurally, the benefit of having the RRBs follow the geographical boundaries of the 
federal circuit courts is that if there are legal suits filed against the investigators in any of these 
RRB-approved cases later, the district and circuit courts will be able to look at the RRB approval 
summary statement to gain a better understanding as to why the protocol was approved. (See 
Table 5). Undoubtedly, the RRB opinion will not be binding on the court, but it can serve as 
expert opinion and evidence as to what happened in the protocol review process. For example, 
under this new review board system the recruitment of children who were "at-risk" of lead 
poisoning to live in partially lead-abated houses in the KKI protocol would have flagged the case 
to go to RRB review because it would be debatable whether these children had a "condition or 
disorder." If the RRB granted approval, later the Grimes Court could have used the RRB written 
report to help understand why the protocol was approved. One of the goals of creating a 
regional review system is that it may prevent the development of a discrepancy between the 
courts' legally binding opinions and the institutional review board decisions. By providing the 
court system with a comprehensible, detailed summary of the discussion that occurred during 
review, the court will be better able to understand the issues at bar and hopefully will be less 
likely to overstep its bounds without regard to the consequences as did the Grimes court. 
. 
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Table 5: Circuit Court Jurisdiction 
Circuit Court123 
1st Circuit 
2nd Circuit 
3rd Circuit 
4th Circuit 
5th Circuit 
6th Circuit 
7'h Circuit 
8th Circuit 
9lh Circuit 
10'h Circuit 
ll,h Circuit 
12th Circuit 
Geographical Jurisdiction_ 
Maine, Massachusetts, New Hampshire, Puerto Rico and Rhode Island 
Connecticut, New York and Vermont 
Delaware, New Jersey, Pennsylvania and Virgin Islands 
Maryland, North Carolina, South Carolina, Virginia and West Virginia 
Louisiana, Mississippi and Texas 
Kentucky, Michigan, Ohio and Tennessee 
Illinois, Indiana and Wisconsin 
Arkansas, Iowa, Minnesota, Missouri, Nebraska, North Dakota and South 
Dakota 
Alaska, Arizona, California, Guam, Hawaii, Idaho, Montana, Nevada, 
Oregon and Washington 
Colorado, Kansas, New Mexico, Oklahoma, Utah and Wyoming 
Alabama, Florida and Georgia 
District of Columbia 
Because members of the RRB will be drawn from several local IRBs and the proposals 
before them will be from a wide geographical area, the chances for a conflict of interest between a 
member of the RRB and a researcher asking for approval is significantly reduced. The RRB 
members will not be placed in the position of having to reject the research of their colleagues 
while at the same time fully aware that their own research needs IRB approval soon. A regional 
review system creates distance between the researcher and the approval process that removes 
local pressures and allows for a better non-biased application of the federal regulations.1:4 
Furthermore, because members would be from different IRBs, they will be encouraged to share 
information about the structure and effectiveness of their own IRB so that they may learn from 
one another. 
Criticism launched against local IRBs has included the inability to police itself 
appropriately. By having a second review board look at contentious protocols, the chances that 
the same biases or improper review processes will occur diminishes and respect for the local IRB 
123 There is also a Federal Circuit which has nationwide jurisdiction to hear appeals in patent law cases and 
cases decided by the Court of International Trade and the Court of Federal Claims. 
124 The Grimes Court claimed that such pressures were present in the Hopkins’s IRB and contributed to the 
protocol being miscast as having beneficial components for the control groups. 
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system should improve.12' Local IRBs that have received bad press in recent years will be better 
able to regain the trust of their local community if the local community knows that an additional 
regional review may occur when the protocols involve procedures or interventions whose risks 
are not easily classified. 
The National Review Board will consist of one member of each RRB and should meet at 
least four times a year. Additional members should include experts in different disciplines and 
segments of society, as is required by §46.107, but total membership should not exceed 20. 
Membership may be derived from large and small institutions, policymakers, ethicists, lawyers, 
patients, and advocates for vulnerable populations. Members will serve a maximum of five years 
in order to create an evolving board that keeps up with developing ethical understandings, 
changes in law and advances in types of medical research. It will also prevent the members from 
becoming complacent in their duties. All members will be required to undergo extensive 
educational training on research ethics and the federal regulations similar to the RRB 
requirements for membership. NRB members should also have a thorough understanding of the 
OHRP, the history and reports of the various committees that have been formed to address 
human research issues (the National Commission, NHRPAC Workgroup etc.) and why or why 
not these committees have been successful in carrying out their charges. The NRB should aspire 
to be the most successful of any of these bodies and draw upon the experiences of these prior 
committees. 
The NRB's duties will be to review those protocols that the RRBs ask it to review, grant 
appellate review when an investigator has been denied at the IRB and RRB level (exceedingly 
125 Note that the local IRBs are not entirely bypassed by this new system. They remain the initial reviewers 
and are able to decide when to send a protocol for RRB review. Cf. Robert J. Levine & Louis Lasagna, 
Demystifying Central Review Boards: Current Options and Future Directions, IRB: A Review OF HUMAN 
SUBJECTS Research, 1-8, (Nov-Dec 2000). In his discussion of Central Review Boards, Levine asserts 
that academically oriented IRBs are unlikely to delegate the entirety of their responsibilities to an off-site 
review board. 
. 
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rare),126 and most importantly, draft memoranda that will clarify the language in the federal 
regulations. 
In its case-review duties, the NRB will have access to the summary opinions from all 
twelve of the RRBs, plus a member from each RRB present at the meetings, and will be in the best 
position to apply consistent applications of the regulations. Because it will have a substantially 
smaller case-load than the RRBs, it should have more than adequate time to spend on each case 
that it is asked to review. The NRB should strive to reach consensus opinions, but if this is not 
possible, at least a 2/3 majority should be required before a protocol can be approved. This 
condition admittedly will and should protect human subjects at the expense of limiting some 
important research. Similar to the RRB system, the NRB should write a clear summary opinion 
as to how and why it reached its conclusion. The NRB Chair will appoint a member of the NRB 
to write the opinion for a particular case, and members may write additional concurring or 
dissenting opinions if they wish. 
The NRB will also serve as the "expert panel" for §407 review. Because it will have 
representation from all around the country and members who are experts in the field, there 
should be no need to assemble a separate expert panel. Furthermore, the NRB will be 
knowledgeable about national practices and will ensure that the opinion is not out of line with 
current RRB and IRB decisions. Moreover, by requiring the NRB to address the most problematic 
protocols that raise the most difficult ethical issues, the NRB will begin to understand where the 
real sources of conflict lie and how to best address them. The remainder of §407 will be 
unchanged and the opportunity to consult with additional experts and the opportunity for public 
review and comment will still exist. 
The most important function of the NRB will be to draft memoranda to clarify the 
current federal regulations and make suggestions to Congress regarding amendments to the 
regulations as needed. Through their case decisions, the NRB members will gain experience in 
126 Given that appeals to the NRB are likely to be rare, there should be no need for a certiorari process 
analogous to the U.S. Supreme Court. 
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defining terms such as "minimal risk," "minor increase," "reasonably commensurate," and 
"disorder or condition." Because they will have actual experience with cases that they have had 
to decide whether or not to approve during their case-review duties, they will be in a much better 
position to issue these memoranda than the NHRPAC Working Group, National Bioethics 
Advisory Committee or any of the various other governmental bodies that have called for 
explication of the regulations. Much like a court that hears cases, the NRB will be able to see the 
practical effects of their decisions and therefore prevent interpretative mistakes that are made 
when one deals only with the theoretical application of the regulations. 
Case-based ethical reasoning rather than purely theoretical reasoning will be far superior 
in balancing the advancement of medical research with the protection of the rights and welfare of 
human subjects. The NRB actions will create nationwide impact, and therefore, if their decisions 
are viewed as gravely wrong, researchers will demand changes in the federal regulations. The 
NRB members can consult national experts and use their experience to suggest appropriate 
revisions to Congress. (See Table 6.) 
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Table 6: Membership and Duties of New Review Board System 
Board Membership Functions/Expertise 
Local 
Institutional 
Review Board 
(IRBs) 
As currently defined 
by §46.107 (at least 
five members, 
diversity of 
backgrounds, at least 
one member with 
expertise in a 
scientific area and on 
member with 
expertise in a 
nonscientific area, 
one member not 
affiliated with the 
institution) 
• review research as currently conducted under §46.108 and §46.109 
except: 
protocols that involve interventions or procedures that not clearly 
minimal risk or less may be forwarded to the appropriate RRB 
for review accompanied by a statement for why review is 
requested 
protocols falling under §405 and §406 that are contentious due to 
reliance on ambiguous regulatory language and have no prior 
precedent for approval must be forwarded to the appropriate 
RRB for review 
protocols seeking §407 review must be forwarded to the NRB for 
review 
• review protocols as currently conducted under §46.110 (expedited 
review) 
• maintain familiarity with local institution conditions and investigators 
• continue to work closely with investigators to assure human subject 
protection 
• educate investigators, board members and community members 
regarding research ethics 
• where not otherwise stated, the current IRB functions will continue 
Specific Advantages: 
• experience with reviewing large number of protocols best enables them 
to identify ambiguities in the regulations and problems with their 
application and send protocols exemplifying these problems to the RRB 
level 
Regional 
Review Boards 
(RRBs) 
• no more than one 
member from each 
local 1RB 
• revolving 
membership so that 
each RRB has no 
more than 30 
members and over 
years, local IRBs 
have the opportunity 
to have a 
representative serve 
as a member of their 
RRB 
• membership not to 
exceed 3 years 
• review all protocols forwarded by IRBs 
• appellate function for investigators denied at local level 
• send protocols for review to NRB at RRB’s discretion, but no more than 
20% of all protocols may be sent 
• draft case summaries after making a decision and circulate that decision 
to the NRB and the local IRB who conducted the initial review 
• maintain familiarity with local IRBs decisions 
Specific Advantages: 
• information sharing between members from different institutions at 
regional meetings 
• time available to discuss areas of regulations that are ambiguous such as 
“minor increase” “disease or condition" “vital importance" etc. and make 
decisions accordingly 
National 
Review Board 
(NRB) 
• 12 members (one 
from each RRB) 
• additional 
members, not to 
exceed 8, drawn from 
areas not otherwise 
represented by the 
RRB representatives; 
these may be 
investigators, 
lawyers, ethicists etc. 
• membership not to 
exceed 5 years 
• review all protocols forwarded by RRBs 
• review all §407 protocols 
• appellate function for investigators denied at regional level 
• draft memoranda to clarify federal regulations as needed 
• maintain familiarity with state and federal court cases involving human 
subjects research and research ethics 
• recommend changes to Congress as needed 
• maintain familiarity with research studies nationwide and RRB review 
decisions 
Specific Advantages: 
• ability to spend time drafting memoranda to clarify federal regulations 
drawing upon their knowledge of the entire review board system and their 
experience as a reviewing body 
• 
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Indeed, one might argue that a hierarchical review board system will be unwieldy and 
approval of research protocols will take too long, but that is all the more reason to design the 
system to function efficiently. With appropriate parsing of duties between the local, regional and 
national review boards, each group can function more efficiently and ideally, with a lesser 
workload. A more centralized review organization encourages greater consistency, but 
maintaining the local IRBs and including 12 RRBs still allows for flexibility within the system. 
Local IRBs also reserve their autonomy as they are the ones that decide which protocols to send 
to the RRB. It may be that local IRBs will not handle this responsibility appropriately or refuse to 
send protocols to their RRB. Although it is beyond the scope of this paper, such malfunctioning 
within the local IRBs possibly could be dealt with by the accreditation systems that are in place 
and beginning to function.127 Above the local level, the regional review system and the 
requirement of creating a database of written summary opinions is designed to produce 
information sharing between IRBs and there is incredible value to knowing how other local IRBs 
operate. It seems clear that the Yale system, which uses a primary reviewer process, is believed 
to work well,12* but certainly it is not the only method being used.12M Local IRBs would benefit 
from learning about each other's processes to help increase efficiency and awareness of difficult 
protocol decisions that are made. A hierarchical IRB system creates the opportunity for each 
review board level to foster and develop specific strengths that will ultimately afford greater 
protections for human subjects in clinical research. 
Conclusion 
Unethical research involving children has occurred throughout history. Only in recent 
years have federal regulations been enacted in the United States to help prevent further 
127 For information on accreditation programs, see the Association for the Accreditation of Human 
Research Protection Programs, Inc. at: <http://www.aahrpp.org>. 
128 See Levine, supra note 5, 328-341, for in depth look at Yale’s IRB system. 
129 See David A. Blake, An Executive Committee System for IRBs, IRB: A REVIEW OF HUMAN SUBJECTS 
RESEARCH, 8-9 (Nov 1982), for comparison of primary review system with Johns Hopkins executive 
committee system. 
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violations of human rights. The federal regulations are routed in the principles of respects for 
persons, beneficence and justice. They create a valuable risk-based assessment system for 
evaluating research protocols, but the regulations are fraught with imprecise language that often 
leads to their inconsistent application and incongruous results. The KKI lead abatement study, 
the Amiel and NICHD studies of children who were at risk for diabetes and obesity respectively, 
and the human growth hormone studies are just a few examples of protocols that, however well- 
intended, received widely differing views of their acceptability, and ultimately had diverse 
outcomes. The definitions of "minor increase," "reasonably commensurate," and "disorder or 
condition" continue to plague those who are charged with interpreting the regulations. 
The ambiguities in the federal regulations make them inherently difficult to apply and 
because IRBs are charged with their application but not their revision, the IRBs are often blamed 
for inconsistent and ineffective applications. Amidst the confusion over how to interpret words 
in the regulations, it is not surprising that despite their best efforts individual IRBs have been 
criticized for inappropriately accepting or denying research protocols. Clarification of the 
regulations protecting children are inevitably needed, but the substantive changes to the 
regulations will not be realized without first making procedural changes. The IRBs cannot take 
on the additional duties of interpreting and possibly revising the regulations when they provide 
inadequate guidance. 
A new review board system, modeled after the federal court system, will redistribute 
some of these responsibilities and create boards that are better able to carry out their specific 
mandates. Local IRBs will continue to oversee minimal risk research, but will not be solely 
responsible for interpreting the more ambiguous definitions in the regulations. Regional review 
boards, with members who are well educated on research ethics and federal regulations, will 
assume some of these duties. Finally, a national review board, which has some case-review 
duties, will be best able use case-based ethical reasoning and carry out the mandate of drafting 
memoranda that clarify the federal regulations and recommending changes to Congress as 
needed. An overhaul of the review board system seems like a rather drastic proposal, but it may 
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serve as the best way to efficiently and effectively ensure the protection of human subjects, 
including children, according to the principles of respect for persons, beneficence and justice. 

57 
Appendix 1 
Department of Health and Human Services, 
45 Code of Federal Regulations 46, Subpart D 
TITLE 45 - PUBLIC WELFARE 
SUBTITLE A - DEPARTMENT OF HEALTH AND HUMAN SERVICES 
SUBCHAPTER A - GENERAL ADMINISTRATION 
PART 46 - PROTECTION OF HUMAN SUBJECTS 
SUBPART D - ADDITIONAL PROTECTIONS FOR CHILDREN INVOLVED AS SUBJECTS 
IN RESEARCH 
§ 46.401 To what do these regulations apply? 
(a) This subpart applies to all research involving children as subjects, conducted or supported by 
the Department of Health and Human Services. 
(1) This includes research conducted by Department employees, except that each head of an 
Operating Division of the Department may adopt such nonsubstantive, procedural modifications 
as may be appropriate from an administrative standpoint. 
(2) It also includes research conducted or supported by the Department of Health and Human 
Services outside the United States, but in appropriate circumstances, the Secretary may, under 
paragraph (e) of § 46.101 of Subpart A, waive the applicability of some or all of the requirements 
of these regulations for research of this type. 
(b) Exemptions at § 46.101(b)(1) and (b)(3) through (b)(6) are applicable to this subpart. The 
exemption at § 46.101(b)(2) regarding educational tests is also applicable to this subpart. 
However, the exemption at § 46.101(b)(2) for research involving survey or interview procedures 
or observations of public behavior does not apply to research covered by this subpart, except for 
research involving observation of public behavior when the investigator(s) do not participate in 
the activities being observed. 
(c) The exceptions, additions, and provisions for waiver as they appear in paragraphs (c) through 
(i) of § 46.101 of Subpart A are applicable to this subpart. 
§ 46.402 Definitions. 
The definitions in § 46.102 of Subpart A shall be applicable to this subpart as well. In addition, as 
used in this subpart: 
(a) Children are persons who have not attained the legal age for consent to treatments or 
procedures involved in the research, under the applicable law of the jurisdiction in which the 
research will be conducted. 
(b) Assent means a child's affirmative agreement to participate in research. Mere failure to object 
should not, absent affirmative agreement, be construed as assent. 
(c) Permission means the agreement of parent(s) or guardian to the participation of their child or 
ward in research. 
(d) Parent means a child's biological or adoptive parent. 
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(e) Guardian means an individual who is authorized under applicable State or local law to 
consent on behalf of a child to general medical care. 
§ 46.403 IRB duties. 
In addition to other responsibilities assigned to IRBs under this part, each IRB shall review 
research covered by this subpart and approve only research which satisfies the conditions of all 
applicable sections of this subpart. 
§ 46.404 Research not involving greater than minimal risk. 
HHS will conduct or fund research in which the IRB finds that no greater than minimal risk to 
children is presented, only if the IRB finds that adequate provisions are made for soliciting the 
assent of the children and the permission of their parents or guardians, as set forth in § 46.408. 
§ 46.405 Research involving greater than minimal risk but presenting the prospect of direct 
benefit to the individual subjects. 
HHS will conduct or fund research in which the IRB finds that more than minimal risk to 
children is presented by an intervention or procedure that holds out the prospect of direct benefit 
for the individual subject, or by a monitoring procedure that is likely to contribute to the subject's 
well-being, only if the IRB finds that: 
(a) The risk is justified by the anticipated benefi t to the subjects; 
(b) The relation of the anticipated benefit to the risk is at least as favorable to the subjects as that 
presented by available alternative approaches; and 
(c) Adequate provisions are made for soliciting the assent of the children and permission of their 
parents or guardians, as set forth in § 46.408. 
§ 46.406 Research involving greater than minimal risk and no prospect of direct benefit to 
individual subjects, but likely to yield generalizable knowledge about the subject's disorder or 
condition. 
HHS will conduct or fund research in which the IRB finds that more than minimal risk to 
children is presented by an intervention or procedure that does not hold out the prospect of 
direct benefit for the individual subject, or by a monitoring procedure which is not likely to 
contribute to the well-being of the subject, only if the IRB finds that: 
(a) The risk represents a minor increase over minimal risk; 
(b) The intervention or procedure presents experiences to subjects that are reasonably 
commensurate with those inherent in their actual or expected medical, dental, psychological, 
social, or educational situations; 
(c) The intervention or procedure is likely to yield generalizable knowledge about the subjects' 
disorder or condition which is of vital importance for the understanding or amelioration of the 
subjects’ disorder or condition; and 
' 
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(d) Adequate provisions are made for soliciting assent of the children and permission of their 
parents or guardians, as set forth in § 46.408. 
§ 46.407 Research not otherwise approvable which presents an opportunity to understand, 
prevent, or alleviate a serious problem affecting the health or welfare of children. 
HHS will conduct or fund research that the IRB does not believe meets the requirements of § 
46.404, § 46.405, or § 46.406 only if: 
(a) The IRB finds that the research presents a reasonable opportunity to further the 
understanding, prevention, or alleviation of a serious problem affecting the health or welfare of 
children; and 
(b) The Secretary, after consultation with a panel of experts in pertinent disciplines (for example: 
science, medicine, education, ethics, law) and following opportunity for public review and 
comment, has determined either: 
(1) That the research in fact satisfies the conditions of § 46.404, § 46.405, or § 46.406, as applicable, 
or 
(2) The following: 
(i) The research presents a reasonable opportunity to further the understanding, prevention, or 
alleviation of a serious problem affecting the health or welfare of children; 
(ii) The research will be conducted in accordance with sound ethical principles; 
(iii) Adequate provisions are made for soliciting the assent of children and the permission of their 
parents or guardians, as set forth in § 46.408. 
§ 46.408 Requirements for permission by parents or guardians and for assent by children. 
(a) In addition to the determinations required under other applicable sections of this subpart, the 
IRB shall determine that adequate provisions are made for soliciting the assent of the children, 
when in the judgment of the IRB the children are capable of providing assent. In determining 
whether children are capable of assenting, the IRB shall take into account the ages, maturity, and 
psychological state of the children involved. This judgment may be made for all children to be 
involved in research under a particular protocol, or for each child, as the IRB deems appropriate. 
If the IRB determines that the capability of some or all of the children is so limited that they 
cannot reasonably be consulted or that the intervention or procedure involved in the research 
holds out a prospect of direct benefit that is important to the health or well-being of the children 
and is available only in the context of the research, the assent of the children is not a necessary 
condition for proceeding with the research. Even where the IRB determines that the subjects are 
capable of assenting, the IRB may still waive the assent requirement under circumstances in 
which consent may be waived in accord with § 46.116 of Subpart A. 
(b) In addition to the determinations required under other applicable sections of this subpart, the 
IRB shall determine, in accordance with and to the extent that consent is required by § 46.116 of 
Subpart A, that adequate provisions are made for soliciting the permission of each child's parents 
or guardian. Where parental permission is to be obtained, the IRB may find that the permission of 
one parent is sufficient for research to be conducted under § 46.404 or § 46.405. Where research is 
covered by §§ 46.406 and 46.407 and permission is to be obtained from parents, both parents 
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must give their permission unless one parent is deceased, unknown, incompetent, or not 
reasonably available, or when only one parent has legal responsibility for the care and custody of 
the child. 
(c) In addition to the provisions for waiver contained in § 46.116 of Subpart A, if the IRB 
determines that a research protocol is designed for conditions or for a subject population for 
which parental or guardian permission is not a reasonable requirement to protect the subjects (for 
example, neglected or abused children), it may waive the consent requirements in Subpart A of 
this part and paragraph (b) of this section, provided an appropriate mechanism for protecting the 
children who will participate as subjects in the research is substituted, and provided further that 
the waiver is not inconsistent with Federal, state or local law. The choice of an appropriate 
mechanism would depend upon the nature and purpose of the activities described in the 
protocol, the risk and anticipated benefit to the research subjects, and their age, maturity, status, 
and condition. 
(d) Permission by parents or guardians shall be documented in accordance with and to the extent 
required by § 46.117 of Sub part A. 
(e) When the IRB determines that assent is required, it shall also determine whether and how 
assent must be documented. 
§ 46.409 Wards. 
(a) Children who are wards of the state or any other agency, institution, or entity can be included 
iir research approved under § 46.406 or § 46.407 only if such research is: 
(1) Related to their status as wards; or 
(2) Conducted in schools, camps, hospitals, institutions, or similar settings in which the majority 
of children involved as subjects are not wards. 
(b) If the research is approved under paragraph (a) of this section, the IRB shall require 
appointment of an advocate for each child who is a ward, in addition to any other individual 
acting on behalf of the child as guardian or in loco parentis. One individual may serve as 
advocate for more than one child. The advocate shall be an individual who has the background 
and experience to act in, and agrees to act in, the best interests of the child for the duration of the 
child's participation in the research and who is not associated in any way (except in the role as 
advocate or member of the IRB) with the research, the investigator(s), or the guardian 
organization. 
•: 
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Appendix 2 
THE NUREMBERG CODE 
Permissible Medical Experiments 
The great weight of the evidence before us to effect that certain types of medical experiments on 
human beings, when kept within reasonably well-defined bounds, conform to the ethics of the 
medical profession generally. The protagonists of the practice of human experimentation justify 
their views on the basis that such experiments yield results for the good of society that are 
unprocurable by other methods or means of study. All agree, however, that certain basic 
principles must be observed in order to satisfy moral, ethical and legal concepts: 
1. The voluntary consent of the human subject is absolutely essential. 
This means that the person involved should have legal capacity to give consent; should 
be so situated as to be able to exercise free power of choice, without the intervention of any 
element of force, fraud, deceit, duress, over-reaching, or other ulterior form of constraint or 
coercion; and should have sufficient knowledge and comprehension of the elements of the 
subject matter involved as to enable him to make an understanding and enlightened decision. 
This latter element requires that before the acceptance of an affirmative decision by the 
experimental subject there should be made known to him the nature, duration, and purpose of 
the experiment; the method and means by which it is to be conducted; all inconveniences and 
hazards reasonably to be expected; and the effects upon his health or person which may possibly 
come from his participation in the experiment. 
The duty and responsibility for ascertaining the quality of the consent rests upon each 
individual who initiates, directs or engages in the experiment. It is a personal duty and 
responsibility which may not be delegated to another with impunity. 
2. The experiment should be such as to yield fruitful results for the good of society, 
unprocurable by other methods or means of study, and not random and unnecessary in nature. 
3. The experiment should be so designed and based on the results of animal experimentation 
and a knowledge of the natural history of the disease or other problem under study that the 
anticipated results will justify the performance of the experiment. 
4. The experiment should be so conducted as to avoid all unnecessary physical and mental 
suffering and injury. 
5. No experiment should be conducted where there is an a priori reason to believe that death or 
disabling injury will occur; except, perhaps, in those experiments where the experimental 
physicians also serve as subjects. 
6. The degree of risk to be taken should never exceed that determined by the humanitarian 
importance of the problem to be solved by the experiment. 
7. Proper preparations should be made and adequate facilities provided to protect the 
experimental subject against even remote possibilities of injury, disability, or death. 
8. The experiment should be conducted only by scientifically qualified persons. The highest 
degree of skill and care should be required through all stages of the experiment of those who 
conduct or engage in the experiment. 
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9. During the course of the experiment the human subject should be at liberty to bring the 
experiment to an end if he has reached the physical or mental state where continuation of the 
experiment seemed to him to be impossible. 
10. During the course of the experiment the scientist in charge must be prepared to terminate the 
experiment at any stage, if he has probably [sic] cause to believe, in the exercise of the good faith, 
superior skill and careful judgment required of him that a continuation of the experiment is likely 
to result in injury, disability, or death to the experimental subject. 
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Appendix 3 
WORLD MEDICAL ASSOCIATION 
DECLARATION OF HELSINKI 
Adopted by the 18th World Medical Assembly Helsinki, Finland, June 1964 
and amended by the 29th World Medical Assembly Tokyo, Japan, October 1975 
35th World Medical Assembly Venice, Italy, October 1983 
and the 41st World Medical Assembly Hong Kong, September 1989 
Introduction 
It is the mission of the physician to safeguard the health of the people. His or her knowledge and 
conscience are dedicated to the fulfillment of this mission. 
The Declaration of Geneva of the World Medical Assembly binds the physician with the words, 
"The health of my patient will be my first consideration," and the International Code of Medical 
Ethics declares that, "A physician shall act only in the patient's interest when providing medical 
care which might have the effect of weakening the physical and mental condition of the patient." 
The purpose of biomedical research involving human subjects must be to improve diagnostic, 
therapeutic and prophylactic procedures and the understanding of the aetiology and 
pathogenesis of disease. 
In current medical practice most diagnostic, therapeutic or prophylactic procedures involve 
hazards. This applies especially to biomedical research. 
Medical progress is based on research which ultimately must rest in part on experimentation 
involving human subjects. 
In the field of biomedical research a fundamental distinction must be recognized between 
medical research in which the aim is essentially diagnostic or therapeutic for a patient, and 
medical research, the essential object of which is purely scientific and without implying direct 
diagnostic or therapeutic value to the person subjected to the research. 
Special caution must be exercised in the conduct of research which may affect the environment, 
and the welfare of animals used for research must be respected. 
Because it is essential that the results of laboratory experiments be applied to human beings to 
further scientific knowledge and to help suffering humanity, the World Medical Association has 
prepared the following recommendations as a guide to every physician in biomedical research 
involving human subjects. They should be kept under review in the future. It must be stressed 
that the standards as drafted are only a guide to physicians all over the world. Physicians are not 
relieved from criminal, civil and ethical responsibilities under the laws of their own countries. 
I. Basic principles 
1. Biomedical research involving human subjects must conform to generally accepted 
scientific principles and should be based on adequately performed laboratory and animal 
experimentation and on a thorough knowledge of the scientific literature. 
2. The design and performance of each experimental procedure involving human subjects 
should be clearly formulated in an experimental protocol which should be transmitted for 
consideration, comment and guidance to a specially appointed committee independent of the 
investigator and the sponsor provided that this independent committee is in conformity with the 
laws and regulations of the country in which the research experiment is performed. 
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3. Biomedical research involving human subjects should be conducted only by scientifically 
qualified persons and under the supervision of a clinically competent medical person. The 
responsibility for the human subject must always rest with a medically qualified person and 
never rest on the subject of the research, even though the subject has given his or her consent. 
4. Biomedical research involving human subjects cannot legitimately be carried out unless 
the importance of the objective is in proportion to the inherent risk to the subject. 
5. Every biomedical research project involving human subjects should be preceded by 
careful assessment of predictable risks in comparison with foreseeable benefits to the subject or to 
others. Concern for the interests of the subject must always prevail over the interests of science 
and society. 
6. The right of the research subject to safeguard his or her integrity must always be 
respected. Every precaution should be taken to respect the privacy of the subject and to minimize 
the impact of the study on the subject's physical and mental integrity and on the personality of 
the subject. 
7. Physicians should abstain from engaging in research projects involving human subjects 
unless they are satisfied that the hazards involved are believed to be predictable. Physicians 
should cease any investigation if the hazards are found to outweigh the potential benefits. 
8. In publication of the results of his or her research, the physician is obliged to preserve the 
accuracy of the results. Reports of experimentation not in accordance with the principles laid 
down in this Declaration should not be accepted for publication. 
9. In any research on human beings, each potential subject must be adequately informed of 
the aims, methods, anticipated benefits and potential hazards of the study and the discomfort it 
may entail. He or she should be informed that he or she is a liberty to abstain from participation 
in the study and that he or she is free to withdraw his or her consent to participation at any time. 
The physician should then obtain the subject's freely-given informed consent, preferably in 
writing. 
10. When obtaining informed consent for the research project the physician should be 
particularly cautious if the subject is in a dependent relationship to him or her or may consent 
under duress. In that case the informed consent should be obtained by a physician who is not 
engaged in the investigation and who is completely independent of this official relationship, 
11. In case of legal incompetence, informed consent should be obtained from the legal 
guardian in accordance with national legislation. Where physical or mental incapacity makes it 
impossible to obtain informed consent, or when the subject is a minor, permission from the 
responsible relative replaces that of the subject in accordance with national legislation. 
Whenever the minor child is in fact able to give a consent, the minor's consent must be obtained 
in addition to the consent of the minor's legal guardian. 
12. The research protocol should always contain a statement of the ethical considerations 
involved and should indicate that the principles enunciated in the present Declaration are 
complied with. 
II. Medical research combined with clinical care (Clinical research) 
1. In the treatment of the sick person, the physician must be free to use a new diagnostic 
and therapeutic measure, if in his or her judgment it offers hope of saving life, reestablishing 
health or alleviating suffering. 
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2. The potential benefits, hazards and discomfort of a new method should be weighed 
against the advantages of the best current diagnostic and therapeutic methods. 
3. In any medical study, every patient - including those of a control group, if any—should be 
assured of the best proven diagnostic and therapeutic method. 
4. The refusal of the patient to participate in a study must never interfere with the 
physician-patient relationship. 
5. If the physician considers it essential not to obtain informed consent, the specific reasons 
for this proposal should be stated in the experimental protocol for transmission to the 
independent committee (I, 2). 
6. The physician can combine medical research with professional care, the objective being 
the acquisition of new medical knowledge, only to the extent that medical research is justified by 
its potential diagnostic or therapeutic value for the patient. 
III. Non-therapeutic biomedical research involving human subjects (Non-clinical biomedical 
research) 
1. In the purely scientific application of medical research carried out on a human being, it is 
the duty of the physician to remain the protector of the life and health of that person on whom 
biomedical research is being carried out. 
2. The subjects should be volunteers—either healthy persons or patients for whom the 
experimental design is not related to the patient's illness. 
3. The investigator or the investigating team should discontinue the research if in his/her 
or their judgment it may, if continued, be harmful to the individual. 
4. In research on man, the interest of science and society should never take precedence over 
considerations related to the well being of the subject. 
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Appendix 4 
Department of Health and Human Services, 
45 Code of Federal Regulations 46, 
Selected Sections Relating to Institutional Review Boards 
TITLE 45 - PUBLIC WELFARE 
SUBTITLE A - DEPARTMENT OF HEALTH AND HUMAN SERVICES 
SUBCHAPTER A - GENERAL ADMINISTRATION 
PART 46 - PROTECTION OF HUMAN SUBJECTS 
SUBPART A - BASIC HHS POLICY FOR PROTECTION OF HUMAN RESEARCH SUBJECTS 
§ 46.103 Assuring compliance with this policy—research conducted or supported by any Federal 
Department or Agency. 
(a) Each institution engaged in research which is covered by this policy and which is conducted 
or supported by a federal department or agency shall provide written assurance satisfactory to 
the department or agency7 head that it will comply with the requirements set forth in this policy. 
In lieu of requiring submission of an assurance, individual department or agency heads shall 
accept the existence of a current assurance, appropriate for the research in question, on file with 
the Office for Protection from Research Risks, HHS, and approved for federalwide use by that 
office. When the existence of an HHS-approved assurance is accepted in lieu of requiring 
submission of an assurance, reports (except certification) required by this policy to be made to 
department and agency heads shall also be made to the Office for Protection from Research Risks, 
HHS. 
(b) Departments and agencies will conduct or support research covered by this policy only if the 
institution has an assurance approved as provided in this section, and only if the institution has 
certified to the department or agency head that the research has been reviewed and approved by 
an IRB provided for in the assurance, and will be subject to continuing review by the IRB. 
Assurances applicable to federally supported or conducted research shall at a minimum include: 
(1) A statement of principles governing the institution in the discharge of its responsibilities for 
protecting the rights and welfare of human subjects of research conducted at or sponsored by the 
institution, regardless of whether the research is subject to federal regulation. This may include 
an appropriate existing code, declaration, or statement of ethical principles, or a statement 
formulated by the institution itself. This requirement does not preempt provisions of this policy 
applicable to department- or agency-supported or regulated research and need not be applicable 
to any research exempted or waived under § 46.101 (b) or (i). 
(2) Designation of one or more IRBs established in accordance with the requirements of this 
policy, and for which provisions are made for meeting space and sufficient staff to support the 
IRB's review and recordkeeping duties. 
(3) A list of IRB members identified by name; earned degrees; representative capacity7; indications 
of experience such as board certifications, licenses, etc., sufficient to describe each member's chief 
anticipated contributions to IRB deliberations; and any employment or other relationship 
between each member and the institution; for example: full-time employee, part-time employee, 
member of governing panel or board, stockholder, paid or unpaid consultant. Changes in IRB 
membership shall be reported to the department or agency head, unless in accord with § 
46.103(a) of this policy, the existence of an HHS-approved assurance is accepted. In this case. 
, 
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change in IRB membership shall be reported to the Office for Protection from Research Risks, 
HHS. 
(4) Written procedures which the IRB will follow (i) for conducting its initial and continuing 
review of research and for reporting its findings and actions to the investigator and the 
institution; (ii) for determining which projects require review more often than annually and 
which projects need verification from sources other than the investigators that no material 
changes have occurred since previous IRB review; and (iii) for ensuring prompt reporting to the 
IRB of proposed changes in a research activity, and for ensuring that such changes in approved 
research, during the period for which IRB approval has already been given, may not be initiated 
without IRB review and approval except when necessary to eliminate apparent immediate 
hazards to the subject. 
(5) Written procedures for ensuring prompt reporting to the IRB, appropriate institutional 
officials, and the department or agency head of (i) any unanticipated problems involving risks to 
subjects or others or any serious or continuing noncompliance with this policy or the 
requirements or determinations of the IRB and (ii) any suspension or termination of IRB 
approval. 
(c) The assurance shall be executed by an individual authorized to act for the institution and to 
assume on behalf of the institution the obligations imposed by this policy and shall be filed in 
such form and manner as the department or agency head prescribes. 
(d) The department or agency head will evaluate all assurances submitted in accordance with this 
policy through such officers and employees of the department or agency and such experts or 
consultants engaged for this purpose as the department or agency head determines to be 
appropriate. The department or agency head's evaluation will take into consideration the 
adequacy of the proposed IRB in light of the anticipated scope of the institution's research 
activities and the types of subject populations likely to be involved, the appropriateness of the 
proposed initial arid continuing review procedures in light of the probable risks, and the size and 
complexity of the institution. 
(e) On the basis of this evaluation, the department or agency head may approve or disapprove 
the assurance, or enter into negotiations to develop an approvable one. The department or 
agency head may limit the period during which any particular approved assurance or class of 
approved assurances shall remain effective or otherwise condition or restrict approval. 
(f) Certification is required w7hen the research is supported by a federal department or agency 
and not otherwise exempted or waived under § 46.101 (b) or (i). An institution with an approved 
assurance shall certify^ that each application or proposal for research covered by the assurance 
and by § 46.103 of this Policy has been reviewed and approved by the IRB. Such certification 
must be submitted with the application or proposal or by such later date as may be prescribed by 
the department or agency to w7hich the application or proposal is submitted. Under no condition 
shall research covered by § 46.103 of the Policy be supported prior to receipt of the certification 
that the research has been reviewed and approved by the IRB. Institutions without an approved 
assurance covering the research shall certify' within 30 days after receipt of a request for such a 
certification from the department or agency, that the application or proposal has been approved 
by7 the IRB. If the certification is not submitted within these time limits, the application or 
proposal maybe returned to the institution. 
§ 46.107 IRB membership. 
(a) Each IRB shall have at least five members, with varying backgrounds to promote complete 
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and adequate review of research activities commonly conducted by the institution. The IRB shall 
be sufficiently qualified through the experience and expertise of its members, and the diversity of 
the members, including consideration of race, gender, and cultural backgrounds and sensitivity 
to such issues as community attitudes, to promote respect for its advice and counsel in 
safeguarding the rights and welfare of human subjects. In addition to possessing the professional 
competence necessary to review specific research activities, the IRB shall be able to ascertain the 
acceptability of proposed research in terms of institutional commitments and regulations, 
applicable law, and standards of professional conduct and practice. The IRB shall therefore 
include persons knowledgeable in these areas. If an IRB regularly reviews research that involves 
a vulnerable category of subjects, such as children, prisoners, pregnant women, or handicapped 
or men tally disabled persons, consideration shall be given to the inclusion of one or more 
individuals who are knowledgeable about and experienced in working with these subjects. 
(b) Every nondiscriminatory effort will be made to ensure that no IRB consists entirely of men or 
entirely of women, including the institution's consideration of qualified persons of both sexes, so 
long as no selection is made to the IRB on the basis of gender. No IRB may consist entirely of 
members of one profession. 
(c) Each IRB shall include at least one member whose primary concerns are in scientific areas and 
at least one member whose primary concerns are in nonscientific areas. 
(d) Each IRB shall include at least one member who is not otherwise affiliated with the institution 
and who is not part of the immediate family of a person who is affiliated with the institution. 
(e) No IRB may have a member participate in the IRB's initial or continuing review of any project 
in which the member has a conflicting interest, except to provide information requested by the 
IRB. 
(f) An IRB may, in its discretion, invite individuals with competence in special areas to assist in 
the review of issues which require expertise beyond or in addition to that available on the IRB. 
These individuals may not vote with the IRB. 
§ 46.108 IRB functions and operations. 
In order to fulfill the requirements of this policy each IRB shall: 
(a) Follow written procedures in the same detail as described in § 46.103(b)(4) and, to the extent 
required by, § 46.103(b)(5). 
(b) Except when an expedited review procedure is used (see § 46.110), review proposed research 
at convened meetings at which a majority of the members of the IRB are present, including at 
least one member whose primary concerns are in nonscientific areas. In order for the research to 
be approved, it shall receive the approval of a majority of those members present at the meeting. 
§ 46.109 IRB Review of Research. 
(a) An IRB shall review and have authority to approve, require modifications in (to secure 
approval), or disapprove all research activities covered by this policy. 
(b) An IRB shall require that information given to subjects as part of informed consent is in 
accordance with § 46.116. The IRB may require that information, in addition to that specifically 
mentioned in § 46.116, be given to the subjects when in the IRB's judgment the information 
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would meaningfully add to the protection of the rights and welfare of subjects. 
(c) An 1RB shall require documentation of informed consent or may waive documentation in 
accordance with § 46.117. 
(d) An IRB shall notify investigators and the institution in writing of its decision to approve or 
disapprove the proposed research activity, or of modifications required to secure IRB approval of 
the research activity. If the IRB decides to disapprove a research activity, it shall include in its 
written notification a statement of the reasons for its decision and give the investigator an 
opportunity to respond in person or in writing. 
(e) An IRB shall conduct continuing review of research covered by this policy at intervals 
appropriate to the degree of risk, but not less than once per year, and shall have authority to 
observe or have a third party observe the consent process and the research. 
§ 46.110 Expedited review procedures for certain kinds of research involving no more than 
minimal risk, and for minor changes in approved research. 
(a) The Secretary, HHS, has established, and published as a Notice in the FEDERAL REGISTER, 
a list of categories of research that may be reviewed by the IRB through an expedited review 
procedure. The list will be amended, as appropriate after consultation with other departments 
and agencies, through periodic republication by the Secretary, HHS, in the FEDERAL REGISTER. 
A copy of the list is available from the Office for Protection from Research Risks, National 
Institutes of Health, HHS, Bethesda, Maryland 20892. 
(b) An IRB may use the expedited review procedure to review either or both of the following: 
(1) Some or all of the research appearing on the list and found by the reviewer(s) to involve no 
more than minimal risk, 
(2) Minor changes in previously approved research during the period (of one yrear or less) for 
which approval is authorized. 
Under an expedited review' procedure, the review may be carried out by the IRB chairperson or 
by one or more experienced reviewers designated by the chairperson from among members of 
the IRB. In reviewing the research, the reviewers may exercise all of the authorities of the IRB 
except that the reviewers may not disapprove the research. A research activity may be 
disapproved only after review in accordance with the non-expedited procedure set forth in § 
46.108(b). 
(c) Each IRB w'hich uses an expedited review procedure shall adopt a method for keeping all 
members advised of research proposals which have been approved under the procedure. 
(d) The department or agency head may restrict, suspend, terminate, or choose not to authorize 
an institution's or IRB's use of the expedited review procedure. 
§ 46.111 Criteria for IRB approval of research. 
(a) In order to approve research covered by this policy the IRB shall determine that all of the 
following requirements are satisfied: 
(1) Risks to subjects are minimized: (i) By' using procedures w-hich are consistent with sound 
research design and which do not unnecessarily expose subjects to risk, and (ii) whenever 
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appropriate, by using procedures already being performed on the subjects for diagnostic or 
treatment purposes. 
(2) Risks to subjects are reasonable in relation to anticipated benefits, if any, to subjects, and the 
importance of the knowledge that may reasonably be expected to result. In evaluating risks and 
benefits, the IRB should consider only those risks and benefits that may result from the research 
(as distinguished from risks and benefits of therapies subjects would receive even if not 
participating in the research). The IRB should not consider possible long-range effects of applying 
knowledge gained in the research (for example, the possible effects of the research on public 
policy) as among those research risks that fall within the purview' of its responsibility. 
(3) Selection of subjects is equitable. In making this assessment the IRB should take into account 
the purposes of the research and the setting in which the research will be conducted and should 
be particularly cognizant of the special problems of research involving vulnerable populations, 
such as children, prisoners, pregnant women, mentally disabled persons, or economically or 
educationally disadvantaged persons. 
(4) Informed consent will be sought from each prospective subject or the subject's legally 
authorized representative, in accordance with, and to the extent required by § 46.116. 
(5) Informed consent will be appropriately documented, in accordance wdth, and to the extent 
required bv § 46.117. 
(6) When appropriate, the research plan makes adequate provision for monitoring the data 
collected to ensure the safety of subjects. 
(7) When appropriate, there are adequate provisions to protect the privacy of subjects and to 
maintain the confidentiality of data. 
(b) When some or all of the subjects are likely to be vulnerable to coercion or undue influence, 
such as children, prisoners, pregnant women, mentallv disabled persons, or economically or 
educationally disadvantaged persons, additional safeguards have been included in the study to 
protect the rights and welfare of these subjects. 
§ 46.114 Cooperative research. 
Cooperative research projects are those projects covered by this policy which involve more than 
one institution. In the conduct of cooperative research projects, each institution is responsible for 
safeguarding the rights and welfare of human subjects and for complying with this policy. With 
the approval of the department or agency head, an institution participating in a cooperative 
project may enter into a joint review arrangement, rely upon the review of another qualified IRB, 
or make similar arrangements for avoiding duplication of effort. 
§ 46.115 IRB records. 
(a) An institution, or when appropriate an IRB, shall prepare and maintain adequate 
documentation of IRB activities, including the following: 
(1) Copies of all research proposals reviewed, scientific evaluations, if any, that accompany the 
proposals, approved sample consent documents, progress reports submitted by investigators, 
and reports of injuries to subjects. 
(2) Minutes of IRB meetings which shall be in sufficient detail to show attendance at the 
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meetings; actions taken by the IRB; the vote on these actions including the number of members 
voting for, against, and abstaining; the basis for requiring changes in or disapproving research; 
and a written summary of the discussion of controverted issues and their resolution. 
(3) Records of continuing review activities. 
(4) Copies of all correspondence between the IRB and the investigators. 
(5) A list of IRB members in the same detail as described is § 46.103(b)(3). 
(6) Written procedures for the IRB in the same detail as described in § 46.103(b)(4) and § 
46.103(b)(5). 
(7) Statements of significant new findings provided to subjects, as required by § 46.116(b)(5). 
(b) The records required by this policy shall be retained for at least 3 years, and records relating 
to research which is conducted shall be retained for at least 3 years after completion of the 
research. All records shall be accessible for inspection and copying by authorized representatives 
of the department or agency7 at reasonable times and in a reasonable manner. 
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